先端医療シリーズ38　皮膚疾患の最新医療

出版社： 先端医療技術研究所
著者：
発行日： 2006-02-27
分野： 臨床医学：内科  >  皮膚科
ISBN： 4925089471
電子書籍版： 2006-02-27 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
品切れ

9,218 円(税込)

電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

4,610 円(税込)

購入する

商品紹介

皮膚疾患の最新情報を満載！　本書を通して皮膚科学の最近のダイナミックな研究の展開を実感していただき、皮膚科学の新たな息吹を感じてほしい！

目次

  • 先端医療シリーズ38　皮膚疾患の最新医療

    ―目次―

    第1章 皮膚科治療のトピックス
    第2章 皮膚科の新しい治療薬
    第3章 皮膚の生理と病理
    第4章 アトピー性皮膚炎
    第5章 接触皮膚炎･蕁麻疹
    第6章 自己免疫性水疱症
    第7章 膠原病
    第8章 感染症
    第9章 遺伝性皮膚疾患
    第10章 その他の非腫瘍性皮膚疾患
    第11章 光線と皮膚
    第12章 悪性黒色腫
    第13章 皮膚のリンフォーマ
    第14章 ダーモスコピー

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1章 皮膚科治療のトピックス

P.4 掲載の参考文献
1) Krutmamn J, et al:High-dose UVA1 therapy in the treatment of patients with atopic dermatitis. J Am Acad Dermatol 26:225-230, 1992
PubMed
2) Stege H, et al:High-dose UVA1 for urticaria pigmentosa. Lancet 347:64, 1996
PubMed
3) Stege H, et al:Highdose UVA1 radiation therapy for localized scleroderma. J Am Acad Dermatol 36:938-944, 1997
PubMed
4) Morita A, et al:Ultraviolet A1 (340-400nm) phototherapy for scleroderma in systemic sclerosis. J Am Acad Dermatol 43:670-674, 2000
 
5) Plettenberg H, et al:Ultraviolet A1 (340-400nm) phototherapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 41:47-50, 1999
 
6) Krutmann J, et al:High-dose UVA1 therapy for atopic dermatitis:Results of a multicenter trial. J Am Acad Dermatol 38:589-593, 1998
PubMed
7) Kowalzick L, et al:Low dose versus medium dose UV-A1 treatment in severe atopic eczema. Acta Derm Venereol 75:43-45, 1995
PubMed
8) Abeck D, et al:Long-term efficacy of medium-dose UVA1 phototherapy in atopic dermatitis. J Am Acad Dermatol 42:254-257, 2000
PubMed
9) Krutmann J, et al:Mechanisms of ultraviolet (UV) B and UVA phototherapy. J Investing Denmatol Symp Proc 4:70-72, 1999
 
10) Morita A, et al:Evidence that singlet oxygen-induced human T-helper cell apoptosis is the basic mechanism of ultraviolet-A radiation phototherapy. J Exp Med 186:1763-1768, 1997
 
11) Yamauchi R, et al:Different Susceptibility of Malignant versus Nonmalignant Human T-cells Towards Ultraviolet A-1 Radiation-Induced Apoptosis. J Invest Dermatol 122:477-483, 2004
 
12) Godar DE:Light and death:photons and apoptosis. J Investig Dermatol Symp Proc 4:17-23, 1999
PubMed
13)森出明理:紫外線と細胞応答.蛋白質核酸酵素 44:2517-2522, 1999
 
14) Krutmann J, et al:Therapeutic photomedicine phototherapy, Freedberg IM, et al (ed):Fitzpatrick's dermatology in general medicine, 6th ed. McGraw-Hill, New York, p2469-2477, 2003
 
15) 森田明理ほか:尋常性乾癬に対するNarrow-band UVB療法.日皮会誌 111:1229-1236, 2001
 
16) George SA, et al:Narrow-band (TL-01) UVB air-conditioned phototherapy for chronic severe adult atopic dermatitis. Br J Dermatol 128:49-56, 1993
PubMed
17) Green C, et al:311 nm UVB phototherapy--an effective treatment for psoriasis. Br J Dermatol 119:691-696, 1988
PubMed
18) Der-Petrossian M, et al:Half-side comparison study on the efficacy of 8-methoxypsoralen bath-PUVA versus narrow-band ultraviolet B phototherapy in patients with severe chronic atopic dermatitis. Br J Dermatol 142:39-43, 2000
 
19) Young AR:Carcinogenicity of UVB phototherapy assessed. Lancet 345:1431-1432, 1995
 
P.8 掲載の参考文献
1) Pass HI:Review. Photodynamic therapy in oncology:Mechanisms and clinical use. J Natl Cancer Inst 85:443-456, 1993
PubMed
2) Dolphin D:1993 syntex award lecture. Photomedicine and photodynamic therapy. Can J Chem 72:1005-1013, 1993
 
3) Hayata Y, et al:Hematoporphyrin derivative and laser photoradiation in the treatment of lung cancer. Chest 81:269-277, 1982
PubMed
4) Kennedy JC, et al:Photodynamic therapy with endogenous protoporphyrin IX:basic principles and present clinical experience. J Photochem Photobiol B 6:143-148, 1990
PubMed
5) 松本義也:光線力学的療法.診断の皮膚疾患への応用. 皮膚病診療 22:235-239, 2000
 
6) 伊藤嘉恭ほか:Photodynamic therapy.皮膚疾患への応用-.皮膚病診療 22:1185-1190, 2000
 
7) Fritsch C, et al:Photodynamic diagnosis and therapy in dermatology. Skin Pharmacol Appl Skin Physiol 11:358-373, 1998
PubMed
8) Peng TI, et al:Mitochondrion-targeted photosensitizer enhances the photodynamic effect-induced mitochondrial dys-function and apoptosis. Ann N Y Acad Sci 1042:419-428, 2005
 
9) Nakaseko H, et al:Histological changes and involvement of apoptosis after photodynamic therapy for actinic keratoses. Br J Dermatol 148:122-127, 2003
PubMed
10) 中島 進ほか:PDTの原理と光感受性物質の動向, 加藤治文監修:PDTハンドブック-光線力学的治療のアドバンストテクニック. 医学書院, 東京, p1-10, 2002
 
11) Morton CA, et al:Guidelines for topical photodynamic therapy:report of a workshop of the British Photodermatology Group. Br J Dermatol 146:552-567, 2002
PubMed
12) 松本義也ほか:皮膚科領域におけるPDTの治療効果. 臨皮 57:139-143, 2003
 
13) Mikasa K, et al:5-aminolevulinic acid-based photodynamic therapy for the treatment of two patients with extramammary Paget's disease. J Dermatol 32:97-101, 2005
PubMed
14) Itoh Y, et al:Photodynamic therapy of acne vulgaris with topical s-aminolaevulinic acid and incoherent light in Japanese patients. Br J Dermatol 144:575-579, 2001
 
15) 清水純子ほか:Photodynamic diagnosis (PDD) が腫瘍細胞の潤範囲確認に有用であった乳房外Paget病 (陰部) の2例. 日皮会誌 111:1501-1504, 2001
 
P.12 掲載の参考文献
1) 渡辺晋-:レーザー療法,玉置邦彦編:最新皮膚科学大系. 中山書店, 東京,p190-199,2003
 
2) Watanabe S, Takahashi H:Treatment of nevus of Ota with the Q-switched ruby laser. N Engl J Med 331:1745-1750, 1994
 
3) 渡辺晋-:色素性母斑に対するレーザー治療 (Qスイッチレーザー). Visual Dermatology 2:1186-1188, 2003
 
4) 渡辺晋-:シミ・ソバカスの実態.香粧会誌 24:287-295, 2000
 
5) 渡辺晋-:レーザー脱毛.Aesthetic Dermatology 13:83-91, 2003
 
P.16 掲載の参考文献
1) 占川福実ほか:日本皮膚科学会ケミカルピーリングガイドライン2004.日皮会誌 114:953, 2004
 
2) Rawlings A et al:The effect of glycerol and humidity on desmosome degradation in stratum corneu. Arch Dermatol Res 287:457-464, 1995
 
3) Ashida Y, et al:Epidermal interleukin-1 alpha generation is amplified at low humidity:implications for the pathogenesis of inflammatory dermatoses. Br J Dermatol 144:238-243, 2001
PubMed
4) Kim SJ, et al:Increased in vivo collagen synthesis and in vitro cell proliferative effect of glycolic acid. Dermatol Surg 24:1054-1058, 1998
PubMed
5) Bernstein EF, et al:Glycolic acid treatment increases type I collagen mRNA and hyaluronic acid content of human skin. Dermatol Surg 27:429-433, 2001
PubMed
6) Ando S et al:Tyrosinase gene transcription and its control by melanogenic inhibitors. J Invest Dermatol 100:150S-155S, 1993
PubMed
7) Usuki A, et al:The inhibitory effect of glycolic acid and lactic acid on melanin synthesis in melanoma cells. Exp Dermatol 12:43-50, 2003
PubMed
8) Yamamoto Y, et al:Effects of phenol peeling on dermal endothelial cells. J Dermatol Sci 35:158-161, 2004
PubMed
9) 大日輝記ほか:サリチル酸マクロゴールピーリングによる光老化光発癌性の抑制効果.Aesthe Dematol 14:30-39, 2004
 
P.20 掲載の参考文献
1) 柳沢-明ほか:悪性血管内皮細胞腫の1例. 西日皮膚 44:780-789, 1982
 
2) 増澤幹男:悪性血管内皮細胞腫.皮膚病診療 13:223-226, 1991
 
3) 増澤幹男:血管肉腫. 老年医学 43:1203-1206, 2005
Medical*Online
4) 増澤幹男:悪性血管系腫瘍, 玉置邦彦, 飯塚-ほか編:最新皮膚科学大系13 神経系腫瘍間葉系腫瘍. 中山書店, 東京,186-201, 2002
 
5) 前田亜希子ほか:頭蓋内浸潤をきたした皮下型頭部皮膚悪性血管内皮細胞腫-重篤例に対する新たな治療法の試み.日本皮膚科学会雑誌 115:737-742, 2005
 
6) 増澤幹男:血管肉腫の治療戦略:北里大学病院皮膚科2003年度版.日本皮膚科学会雑誌 113:1523-1533, 2003
 
7) 増澤幹男:頭部血管肉腫の治療-rIL-2ワンショット動注法と局所LAK養子免疫療法-. CRC 2:758-763, 1993
 
8) 多田 茂ほか:高齢者頭部血管肉腫の治療-広範囲大量電子線療法の有用性-.口皮会誌 101:1303-1322, 1991
 
9) 榎本詩子ほか:高エネルギーX線照射が奏効した angiosarcomaの肺転移の1例. Skin Cancer 16:93-97, 2001
 
10) 長橋和矢ほか:頭部血管肉腫による血胸への積極的治療-放射線療法とDocetaxel胸腔内投与.日本皮膚科学会雑誌 115:1017-1022, 2005
 
P.24 掲載の参考文献
1) Andre J, et al:Onychomycosis. Int J Dermatol 26:481-490, 1987
PubMed
2) 日本医真菌学会疫学調査委員会:1997年次皮膚真菌症疫学調査成績.日本医真菌学会雑誌 42:11-18, 2001
 
3) 日臨皮在宅医療委員会:高齢者医療と皮膚科.日皮会誌 113:1975-1977, 2003
 
4) Scher RK:Diseases of the nails. Daniel CR III ed. Current Therapy. WB Saunders, Philadelphia, p736, 1990
 
5) Baran R, et al:A new classification of onychomycosis. Br J Dermatol 139:567-571, 1998
PubMed
6) テルビナフィン真菌研究会:爪真菌症に対する多施設共同.無作為化試験によるテルビナフィン125mgの至適投与期間の検討.西日皮膚 67:258-266, 2005
 
7) Elewski BE:The effect of toenail onychomycosis o patient quality of life. Int J Dermatol 36:754-756, 1997
 
8) Drake LA, et al:Effect of onychomycosis on quality of life. J Am Acad Dermatol 38:702-704, 1998
PubMed
9) Firooz A, et al:Itraconazole pulse therapy improves the quality of life of patients with toenail onychomycosis. J Dermatol Treat 14:95-98, 2003
 
10) 谷口彰治ほか:足爪白癬患者のQOL評価.臨皮 59:804-807, 2005
 
11) 渡辺晋-ほか:趾爪白癬患者におけるランダム化二重盲検並行群間比較試験によるイトラコナゾール (ITCZ) パルス療法至適用量.サイクル試験-1年間のフォローアップを含めて-.日皮会誌 114:55-72, 2004
 
12) Baran R, et al:Onychomycosis:The current approach to diagnosis and therapy. Martin Dunitz Ltd, London, p69, 1999
 
P.27 掲載の参考文献
1) Schultz GS, et al:Wound bed preparation:a systematic approach to wound management. Wound Rep Reg 11:1-28, 2003
 
2) Hasan A, et al:Dermal fibroblasts from venous ulcers are unresponsive to action of transforming growth factor-1. J Dermatol Sci 16:59-66, 1997
PubMed
3) Agren MS, et al:Proliferation and mitogenic response to PDGF-BB of fibroblasts isolated from chronic venous leg ulcers is ulcer-age dependent. J Invest Dermatol 112:463-469, 1999
PubMed
4) Cook H, et al:Defective extracellular matrix reorganization by chronic wound fibroblasts is associated with alterations in TIMP-1, TIMP-2, and MMP-2 activity. J Invest Dermatol 115:225-233, 2000
PubMed
5) Mendez MV, et al:Fibroblasts cultured from venous ulcers display cellular characteristics of senescence. J Vasc Surg 28:876-883, 1998
PubMed
6) Higley HR, et al:Extravasation of macromolecules and possible trapping of transforming growth factor-in venous ulceration. Br J Dermatol 132:79-85, 1995
PubMed
7) Bucalo B, et al:Inhibition of cell proliferation by chronic wound fluid. Wound Rep Reg 1:181-186, 1993
 
8) Trengove NJ, et al:Mitogenic activity and cytokine levels in non-healing and healing chronic leg ulcers. Wound Rep Reg 8:13-25, 2000
 
9) Tarnuzzer RW, et al:Biochemical analysis of acute and chronic wound environments. Wound Rep Reg 4:321-325, 1996
 
10) Sato M, et al:Opposite effects of tumour necrosis factor-a on type I and III collagen gene expression by human dermal fibroblasts in monolayer and three-dimensional cultures. Br J Dermatol 138:118-121, 1998
PubMed
11) Ennis WJ, et al:Wound healing at the local level:the stunned wound. Ostomy Wound Manage 46:39S-48S, 2000
PubMed
12) Pollack SV:The wound healing process. Clin Dermatol 2:8-16, 1984
PubMed
13) Rodeheaver GT, et al:Mechanical cleansing of contaminated wounds with a surfactant. Am J Surg 129:241-245, 1975
PubMed
14) Sibbald RG, et al:Screening evaluation of an ionized nanocrystalline silver dressing in chronic wound care. Ostomy Wound Manage 47:38-43, 2001
PubMed
P.28 掲載の参考文献
15) 田中マキ子:創床環境調整 (WBP) と DESINGスケール, 大浦武彦ほか編:Timeの視点による褥瘡ケア.学習研究社, 東京,p9, 2004
 
P.32 掲載の参考文献
1) Verma IM, et al:Gene therapy:twenty-first century medicine. Annu Rev Biochem 74:711-738, 2005
PubMed
2) Hacein-Bey-Abina S, et al:A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 348:255-256, 2003
PubMed
3) 玉井克人ほか:重症アトピー性皮膚炎に対する核酸医薬治療:転写因子NFκBを標的としたデコイDNA軟膏の臨床応用.医学のあゆみ 210:101-104, 2004
 
4) Hengge UR:Progress and prospects of skin gene therapy:a ten year history. Clin Dermatol 23:107-114. 2005
 
9) Watt FM:Stem cell fate and patterning in mammalian epidermis. Curr Opin Genet Dev 11:410-417, 2001
PubMed
10) Coraux C, et al:Reconstituted skin from murine embryonic stem cells. Curr Biol 13:849-853, 2003
PubMed
11) Jiang Y, et al:Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002 Jul 4; 418 (6893):41-49. Epub 2002 Jun 20.
 
12) Sykes M:Mixed chimerism and transplant tolerance. Immunity 14:417-424, 2001
PubMed
P.33 掲載の参考文献
5) 干井克人:表皮水庖症の最新情報.日本医師会雑誌 129:1419-1422, 2003
 
6) Furuse M, et al:Claudin-based tight junctions are crucial for the mammalian epidermal barrier:a lesson from claudin-1-deficient mice. J Cell Biol 156:1099-1111, 2002
 
7) Groth AC, et al:Phage integrases:biology and applications. J Mol Biol 335:667-678, 2004
 
8) Ginsburg DS, et al:Site-specific integration with phiC31 integrase for prolonged expression of therapeutic genes. Adv Genet 54:179-187, 2005
PubMed

第2章 皮膚科の新しい治療薬

P.37 掲載の参考文献
1) Wrone-Smith T, et al:Dermal injection of immunocytes induces psoriasis. J Clin Invest 98:1878-1887, 1996
PubMed
2) Austin LM, et al:The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations:a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol 113:752-759, 1999
 
3) Yawalkar N, et al:Expression of interleukin-12 is increased in psoriatic skin. J Invest Dermatol 111:1053-1057, 1998
PubMed
4) Ettehadi P, et al:Elevated tumour necrosis factor-a (TNF-a) biological activity in psoriatic skin lesions. Clin Exp Immunol 96:146-151, 1994
PubMed
5) Nickoloff BJ, et al:Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis. Am J Pathol 138:129-140, 1991
PubMed
6) Terajima S, et al:An important role of tumor necrosis factor-alpha in the induction of adhesion molecules in psoriasis. Arch Dermatol Res 290:246-252, 1998
PubMed
7) Mizutani H, et al:Role of increased production of monocytes TNF-alpha, IL-1beta and IL-6 in psoriasis:relation to focal infection, disease activity and responses to treatments. J Dermatol Sci 14:145-153, 1997
PubMed
8) Boyman O, et al:Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-a. J Exp Med 199:731-736, 2004
 
9) Lebwohl M, et al:An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 139:719-727, 2003
PubMed
10) Gordon KB, et al:Efalizumab for patients with moderate to severe plaque psoriasis:a randomized controlled trial. JAMA 290:3073-3080, 2003
PubMed
11) Leonardi CL:Efalizumab in the treatment of psoriasis. Dermatol Ther 17:393-400, 2004
PubMed
12) Leonardi CL, et al:Etanercept as monotherapy in patients with psoriasis. N Engl J Med 349:2014-2022, 2003
PubMed
13) Gottlieb AB, et al:Infliximab induction therapy for patients with severe plaque-type psoriasis:a randomized, double-blind, placebo-controlled trial. J Am Acad Dermaltol 51:534-542, 2004
 
14) Kyle S, et al:Guideline for anti-TNF-alpha therapy in psoriatic arthritis. Rheumatology 44:390-397, 2005
PubMed
15) Kauffman CL, et al:A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J Invest Dermatol 123:1037-1044, 2004
PubMed
P.41 掲載の参考文献
1) Liu J, et al:Inhibition of T cell signaling by immunophilin-ligand complexes correlates with loss of calcineurin phosphatase activity. Biochemistry 31:3896-3901, 1992
PubMed
2) Panhans-Gross A, et al:Human epidenrmal Langerhans ユ cells are targets for the immunosuppressive macrolide tacrolimus (FK506). J Allergy Clin Immunol 107:345-352, 2001
 
3) Wollenberg A, et al:Topical tacrolimus (FK506) leads to profound phenotypic and functional alterations of epidermal antigen-presenting dendritic cells in atopic dermatitis. J Allergy Clin Immunol 107:519-525, 2001
PubMed
4) de Paulis A, et al:FK-506, a potent novel inhibitor of the release of proinflammatory mediators from human Fc epsilon R1+cells. J Immunol 146:2374-2381, 1991
 
5) de Paulis A, et al:Anti-inflammatory effect of FK-506 on human skin mast cells. J Invest Dermatol 99:723-728, 1992
PubMed
6) Hom JT, et al:FK506 and rapamycin modulate the functional activities of human peripheral blood eosinophils. Clin Immunol lmmunopathol 68:293-300, 1993
PubMed
7) Kohyama T, et al:A potent immunosuppressant FK506 inhibits IL-8 expression in human eosinophils. Mol Cell Biol Res Commun 1:72-77, 1999
PubMed
8) Sengoku T, et al:FK506 inhibition of histamine release and cytokine production by mast cells and basophils. Int J Immunophamlacol 22:189-201, 2000
 
9) Bos JD, et al:The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol 9:165-169, 2000
PubMed
10) Kyllonen H, et al:Effects of one-year intermittent treatment with topical tacrolimus monotherapy on skin collagen synthesis in patients with atopic dermatitis. Br J Dermatol 150:1174-1181, 2004
PubMed
11) Fleischer AB Jr, et al:Tacrolimus ointment for the treatment of atopic dermatitis is not associated with an increase in cutaneous infections. J Am Acad Dermatol 47:562-570, 2002
 
12) Freeman AK, et al:Tacrolimus oi ltment for the treatment of psoriasis on the face and intertriginous areas. J Am Acad Dermatol 48:564-568, 2003
 
13) Zonnenveld IM, et al:Topical tacrolimus is not effective in chronic plaque psoriasis. A pilot study. Arch Dermatol 134:1101-1102, 1998
 
14) Goldman D:Tacrolimus ointment for the treatment of steroid-induced rosacea:A preliminary report. J Am Acad Dermatol 44:995-998, 2001
PubMed
15) Antille C, et al:Induction of rosaceiform dermatitis during treatment of facial inflammatory dermatoses with tacrolimus ointment. Arch Dermatol 140:457-460, 2004
PubMed
16) Braza TJ, et al:Tacrolimus 0.1% ointment for seborrhoeic dermatitis:An open-label pilot study. Br J Dermatol 148:1242-1244, 2003
 
17) Lener EV, et al:Successful treatment of erosive lichen planus with topical tacrolimus. Arch Dermatol 137:419-422, 2001
PubMed
18) Byrd JA, et al:Response of oral lichen planus to topical tacrolimus in 37 patients. Arch Dermatol 140:1508-1512, 2004
PubMed
20) Kanekura T, et al:Efficacy of topical tacrolimus for treating the malar rash of systemic lupus erythematosus. Br J Dermatol 148:353-356, 2003
PubMed
22) Lepe V, et al:A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. Arch Dermatol 139:581-585, 2003
 
23) Grimes PE, et al:Topical tacrolimus therapy for vitiligo:Therapeutic responses and skin messenger RNA expression of proinflammatory cytokines. J Am Acad Dermatol 51:52-61, 2004
PubMed
P.42 掲載の参考文献
19) 吉田亜希ほか:Actinic dermatitis. Visual Dermatology 3:820-821, 2004
 
21) 浅野善英ほか:限局性強皮症.Visual Dermatology 3:826-827, 2004
 
P.45 掲載の参考文献
1) Komine M, et al:An open trial of oral macrolide treatment for psoriasis vulgaris. J Dermatol 27:508-512, 2000
PubMed
2) 松永義孝ほか:掌せき膿疱症に対するマクロライド療法の臨床応用と表皮角化細胞のケモカイン産生に与えるロキシスロマイシンの影響についての検討.皮膚の科学 1:46-49, 2002
 
3) 西嶋摂子ほか:ルリッド(R)のざそうに対する治療効果.皮膚科紀要 89:287-292, 1994
 
4) Yazawa N, et al:The successful treatment of prurigo pigmentosa with macrolide antibiotics. Dermatology 202:67-69, 2001
PubMed
5) 豊田雅彦ほか:好酸球と14員環系マクロライド系抗生物質:臨床応用を中心として.日皮会誌 113:1449, 2003
 
6) Komine M, et al:Mechanism of thymus-and activation-regulated chemokine (TARC) /CCL17 production and its modulation by roxithromycin. J Invest Dermatol 125:491-498, 2005
PubMed
7) 山西清文ほか:ヒト角化細胞の遺伝子発現に及ぼすロキシスロマイシンの効果.皮膚の科学 1:23-26, 2002
 
8) Yamasaki O, et al:A combination of roxithromycin and imipenem as an antimicrobial strategy against biofilms formed by Staphylococcus aureus. J Antimicrob Chemother 48:573-577, 2001
PubMed
9) Adachi Y, et al:The effect of antibiotics on the production of superantigen from Staphylococcus aureus isolated from atopic dermatitis. J Dermatol Sci 28:76-83, 2002
PubMed
10) Tokura Y, et al:CD8+cell changes in psoriasis associated with roxithromycin-induced clinical improvement. Eur J Dermatol 11:410-415, 2001
PubMed
11) 豊田雅彦ほか:好酸球由来神経成長因了のロキシスロマイシンによる調節作用.皮膚の科学 1:27-31, 2002
 
12) Akamatsu H, et al:Effects of Roxithromycin on the production of lipase and neutrophil chemotactic factor by Propionibacterium Acnes. Dermatology 204:277-280, 2002
PubMed
13) Chen Q, et al:Propionibacterium acnes-induced IL-8 production may be mediated by NF-kappaB activation in human monocytes. J Dermatol Sci 29:97-103, 2002
PubMed
14) Inui S, et al:Potential anti-androgenic activity of roxithromycin in skin. J Dermatol Sci 27:147-151, 2001
PubMed
15) 松吉徳久ほか:線維芽細胞に発現するカドヘリン分子に対するロキシスロマイシンの影響.皮膚の科学 1:36-40, 2002
 
P.49 掲載の参考文献
1) 大滝倫子:老人福祉施設における疥癬の現況.皮膚病診療 19:468-472, 1997
 
2) 永倉貢一ほか:神奈川県の高齢者関連施設での疥癬発生の実態.環境感染 16:216-219, 2001
 
3) 石井則久ほか:東京都皮膚科医会及び神奈川県皮膚科医会の疥癬に関するアンケート調査結果.日皮会誌 113:281-288, 2003
 
4) 大滝倫子:疥癬～診断.治療.予防対策の実際～.化学療法の領域 19:70-74, 2003
 
5) 疥癬診療ガイドライン作成委員会:疥癬診療ガイドライン. 日皮会誌 115:1125-1129, 2005
 
6) 後藤伸之ほか:社会が必要としている医薬品に関する使用実態調査"疥癬の発生状況とその対応".医療薬学 29:665-670, 2003
Medical*Online
7) 大滝倫子:イベルメクチンによる疥癬の治療.臨皮 56 (suppl):165-167, 2002
 
8) 石井則久ほか:疥癬に対するイベルメクチンの効果.臨床皮膚科 57 (suppl):135-138, 2003
 
9) 樹神元博ほか:疥癬に対するイベルメクチンの効果.臨皮 55:273-276, 2001
 
10) 大滝倫子ほか:高齢者施設での疥癬の集団発生に対するイベルメクチンの治療効果.臨皮 59:692-698, 2005
 
11) Pacque M, et al:Safety of and compliance with community-based ivermectin therapy. Lancet 335:1377-1380, 1990
PubMed
12) del Giudice P, et al:Ivermectin in elderly patients. Arch Dermatol 135:351-352, 1999
PubMed
13) del Giudice P:Ivermectin:a new therapeutic weapon in dermatology? Arch Dermatol 135:705-706, 1999
PubMed
14) Barkwell R, et al:Deaths associated with ivermectin treatment of scabies. Lancet 349:1144-1145, 1997
PubMed
15) Bredal WP:Deaths associated with ivermectin for scabies. Lancet 350:216, 1997
PubMed
P.52 掲載の参考文献
1) Salasche S, et al:A review of imiquimod 5% cream for the treatment of various dermatological conditions. Clin Exp Dermatol 28:1-3, 2003
PubMed
2) Sauder D:Imiquimod:modes of action. Br J Dermatol 149:5-8, 2003
PubMed
3) Edwards L, et al:Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human Papilloma Virus. Arch Dermatol 134:25-30, 1998
 
4) Beutner K, et al:Treatment of genital warts with an immune-response modifier (imiquimod). J Am Acad Dermatol 38:230-239, 1998
PubMed
5) Wolf I, et al:Treatment of lentigo maligna (melanoma in situ) with the immulle response modifier imiquimod. Arch Dermatol 141:510-514, 2005
PubMed
6) Steinmann A, et al:Topical imiquimod treatment of a cutaneous melanoma metastasis. J Am Acad Dermatol 43:555-556, 2000
PubMed
7) Mackenzie-Wood A, et al:Imiquimod 5% cream in the treatment of Bowen's disease. J Am Acad Dermatol 44:462-470, 2001
PubMed
8) Martin-Garcia R:Imiquimod:an effective alternative for the treatment of invasive cutaneous squamous cell carcinoma. Dermatol Surg 31:371-374, 2005
PubMed
9) Zampogna J, et al:Treatment of primary limited cutaneous extramammary Paget's disease with topical imiquimod monotherapy:two case reports. J Am Acad Dermatol 47:S229-235, 2002
PubMed
10) Suchin K, et al:Treatment of stage IA cutaneous T-cell lymphoma with topical application of the immune response modifier imiquimod. Arch Dermatol 138:1137-1139, 2002
PubMed
11) Martinez M, et al:Infantile hemangioma:clinical resolution with 5% imiquimod crerm. Arch Dermatol 138:881-884, 2002
PubMed
12) Berman B, et al:Pilot study of the effect of postoperative imiquimod 5% cream on the recurrence rate of excised keloids. J Am Acad Dermatol 47:S209-211, 2002
PubMed
13) Zitelli J:Use of imiquimod for treating skin cancer. J Am Acad Dermatol 52:177, 2005
PubMed

第3章 皮膚の生理と病理

P.56 掲載の参考文献
1) Richard G, et al:Missense mutations in GJB2 encoding connexin-26 cause the ectodermal dysplasia keratitis-ichthyosis-deafness syndrome. Am J Hum Genet 70:1341-1348, 2002
PubMed
2) Ishida-Yamamoto A, et al:Epidermal lamellar granules transport different cargoes as distinct aggregates. J Invest Dermatol 122:1137-1144, 2004
PubMed
3) Jobard F, et al:Lipoxygenase-3 (ALOXE3) and 12 (R)-lipoxygenase (ALOX12B) are mutated in non-bullous congenital ichthyosiform erythroderma (NCIE) linked to chromosome 17p13.1. Hum Mol Genet 11:107-113, 2002
PubMed
4) Lefevre C, et al:Mutations in the transporter ABCA12 are associated with lamellar ichthyosis type 2. Hum Mol Genet 12:2369-2378, 2003
PubMed
5) Akiyama M, et al:Mutations in lipid transporter ABCA12 in harlequin ichthyosis and functional recovery by corrective gene transfer. J Clin Invest 115:1777-1784, 2005
PubMed
6) Kelsell DP, et al:Mutations in ABCA12 underlie the severe congenital skin disease harlequin ichthyosis. Am J Hum Genet 76:794-803, 2005
PubMed
7) Raghunath M, et al:Self-healing collodion baby:a dynamic phenotype explained by a particular transglutaminase-1 mutation. J Invest Derm 120:224-228, 2003
PubMed
8) Kuramoto N, et al:Development of ichthyosiform skin compensates for defective permeability barrier function in mice lacking transglutaminase 1. J Clin Invest 109:243-250, 2002
PubMed
9) Lefevre C, et al:Mutations in ichthyin a new gene on chromosome 5q33 in a new form of autosomal recessive congenital ichthyosis. Hum Mol Genet 13:2473-2482, 2004
 
P.61 掲載の参考文献
1) 豊田雅彦:かゆみの皮膚機序.綜合臨床53:1629-1636, 2004
 
2) 今lll修平:アトピー性皮膚炎の痒みup date-患者では表皮内神経線維が不規則に増加-.MB Derma 104:43-47, 2005
 
3) 高森建二:かゆみの機序,玉置邦彦ほか編:最新皮膚科学大系3湿疹 痒疹 痒症 紅皮症 蕁麻疹.中山書店,東京, p120-127, 2002
 
4) Schmelz M, et al:Specific C-receptors for itch in human skin. J Neurosci 17:8003-8008, 1997
PubMed
5) 江畑俊哉:ヒトにおけるかゆみの評価.医学のあゆみ 197:581-585, 2001
Medical*Online
6) Nakamura M, et al:Pruritogenic mediators in psoriasis vulgaris:comparative evaluation of itch-associated cutaneous factors. Br J Dermatol 149:718-730, 2003
PubMed
7) Toyoda M, et al:Nerve growth factor and substance P are useful plasma markers of disease activity in atopic dermatitis. Br J Dermatol 147:71-79, 2002
PubMed
8) Grewe M, et al:Neurotrophin-4 production by human epidermal keratinocytes:increased expression in atopic dermatitis. J Invest Dermatol 114:1108-1112, 2000
PubMed
9) 豊田雅彦:アトピー性皮膚炎の痒みと神経因子.医学のあゆみ 197:610-611, 2001
 
10) Andoh T, et al:Substance P induction of itch associated response mediated by cutaneous NK1 tachykinin receptors in mice. J Pharmacol Exp Ther 286:1140-1145, 1998
PubMed
11) Kuraishi Y, et al:Scratching behavior induced by pruritogenic but not algesiogenic agents in mice. Eur J Pharmacol 275:229-233, 1995
 
12) Scholzen T, et al:Neuropeptides in the skin:interactions between the neuroendocrine and the skin immune systems. Exp Dermatol 7:81-96, 1998
PubMed
13) 豊田雅彦:神経ペプチドと痒み.MB Derma 104:16-23, 2005
 
14) 高森建二:オピオイド関連治療薬の展望.総合臨床 53:1743-1746, 2004
Medical*Online
15) 熊谷裕生ほか:透析患者の痒みに対するκ‐オピオイド.アゴニストの有効性.MB Derma 104:59-64, 2005
 
P.65 掲載の参考文献
1) Nishimura EK, et al:Dominant role of the niche in melanocyte stem-cell fate determination. Nature 416:854-860, 2002
PubMed
2) Nishimura EK, et al Mechanisms of hair graying:incomplete melanocyte stem cell maintenance in the niche Science 307:720-724, 2005
PubMed
3) Cotsarelis G, et al:Label-retaining cells reside in the bulge area of pilosebaceous unit. implications for follicular stem cells, hair cycle, and skin carcinogenesis. Cell 61:1329-1337, 1990
PubMed
4) Oshima H, et al:Morphogenesis and renewal of hair follicles from adult multipotent stem cells Cel 104:233-245, 2001
 
5) Lavker RM, et al:Hair follicle stem cens:their location, role in hair cycle, and involvement in skin tumor formation. J Invest Dermatol 01:16s-26s, 1993
 
6) Tobin DJ, et al Do hair bulb melanocytes undergo apoptosis during hair follicle regression (catagen)? J Invest Dermatol 111:941-947, 1998
PubMed
7) Okura M, et al:Effects of monoclonal anti-c-kit antibody (ACK2) on melanocytes in newborn mice. J Invest Dermatol 105:322-328, 1995
 
8) Mackenzie MA, et al:Activation of the receptor tyrosine kinase Kit is required for the proliferation of melanoblasts in the mouse embryo. Dev Biol 192:99-107, 1997
PubMed
9) Ortonne JP, et al:Mechanisms that cause abnormal skin color, Nordlund JJ (ed):The Pigmentary System. Oxford University Press, New York, pp489-502, 1998
 
10) Veis DJ, et al:Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair. Cell 75:229-240, 1993
PubMed
11) Nakayama K, et al:Targeted disruption of Bcl-2 alpha beta in mice:occurrence of gray hair, polycystic kidney disease, and lymphocytopenia. Proc Natl Acad Sci USA 91:3700-3704, 1994
PubMed
12) Steingrimsson E, et al:Melanocytes and the microphthalmia transcription factor network. Annu Rev Genet 38:365-411, 2004
PubMed
13) Lerner AB, et al:A mouse model for vitiligo. J Invest Dermatol 87:299-304, 1986
PubMed
14) Horikawa T, et al:DOPA-negative melanocytes in the outer root sheath of human hair follicles express premelanosomal antigens but not a melanosomal antigen or the melanosome-associated glycoproteins tyrosinase, TRP-1, and TRP-2. J Invest Dermatol 106:28-35, 1996
PubMed
15) Narisawa Y, et al:Three-dimensional demonstration of melanocyte distribution of human hair follicles:special reference to the bulge area. Acta Demi Venereol 77:97-101, 1997
 
P.71 掲載の参考文献
1) Rogers MA, et al:The human type I keratin gene family:characterization of new hair follicle specific members and evaluation of the chromosome 17q21.2 gene domain. Differentiation 72:527-540, 2004
PubMed
2) Rogers MA, et al:Characterization of new members of the human type II keratin gene family and a general evaluation of the keratin gene domain on chromosome 12q13.13. J Invest Dermatol 124:536-544, 2005
 
3) Langbein L, et al:The catalog of human hair keratins. I. Expression of the nine type I members in the hair follicle. J Biol Chem 274:19874-19884, 1999
PubMed
4) Langbein L, et al:The catalog of human hair keratins. I. Expression of the six type II members in the hair follicle and the combined catalog of human type I and II keratins. J Biol Chem 276:35123-35132, 2001
PubMed
5) Jave-Suarez LF, et al:Androgen regulation of the human hair follicle:the type I hair keratin hHa7 is a direct target gene in trichocytes. J Invest Dermatol 122:555-564, 2004
PubMed
6) Wang Z, et al:Type II epithelial keratin 6hf (K6hf) is expressed in the companion layer, matrix, and medulla in anagen-stage hair follicles. J Invest Dermatol 121:1276-1282, 2003
PubMed
7) Rogers MA, et al:Characterization of a cluster of human high/ultrahigh sulfur keratin-associated protein genes embedded in the type I keratin gene domain on chromosome 17q12-21. J Biol Chem 276:19440-19451, 2001
PubMed
8) Rogers MA, et al:Characterization of a first domain of human high glycine-tyrosine and high sulfur keratin-associated protein (KAP) genes on chromosome 21q22.1. J Biol Chem 277:48993-49002, 2002
PubMed
9) Rogers MA, et al:Hair keratin associated proteins:characterization of a second high sulfur KAP gene domain on human chromosome 21. J Invest Dermatol 122:147-158, 2004
PubMed
10) Yahagi S, et al:Identification of two novel clusters of ultrahigh-sulfur keratin-associated protein genes on human chromosome 11. Biochem Biophys Res Commun 318:655-664, 2004
PubMed
11) Shimomura Y, et al:Polymorphisms in the human high sulfur hair keratin-associated protein 1, KAP1, gene family. J Biol Chem 277:45493-45501, 2002
PubMed
12) Kariya N, et al:Size polymorphisms in the human ultrahigh sulfur hair keratin-associated protein 4, KAP4, gene family. J Invest Dermatol 124:1111-1118, 2005
PubMed
13) Langbein L, et al:A novel epithelial keratin, hK6irs1, is expressed differentially in all layers of the inner root sheath, including specialized huxley cells (Flugelzellen) of the human hair follicle. J Invest Dermatol 118:789-799, 2002
PubMed
14) Langbein L, et al:K6irs1, K6irs2, K6irs3, and K6irs4 represent the inner-root-sheath-specific type II epithelial keratins of the human hair follicle. J Invest Dermatol 120:512-522, 2003
PubMed
15) Winter H, et al:Mutations in the hair cortex keratin hHb6 cause the inherited hair disease monilethrix. Nat Genet 16:372-374, 1997
PubMed
16) van Steensel MA, et al:A missense mutation in the type II hair keratin hHb3 is associated with monilethrix. J Med Genet 42:e19, 2005
PubMed
17) Chapalain V, et al:Is the loose anagen hair syndrome a keratin disorder? A clinical and molecular study. Arch Dermatol 138:501-506, 2002
PubMed
18) Peters T, et al:Alopecia in a novel mouse model RCO3 is caused by mK6irs1 deficiency. J Invest Dermatol 121:674-680, 2003
 
19) Kikkawa Y, et al:Asmall deletion hotspot in the type II keratin gene mK6irs1/Krt2-6g on mouse chromosome 15, a candidate for causing the wavy hair of the caracul (Ca) mutation. Genetics 165:721-733, 2003
 
P.75 掲載の参考文献
1) Lohi J, et al:Expression of type IV collagen alpha1 (IV) alpha6 (IV) polypeptides in normal and developing human kidney and in renal cell carcinomas and oncocytomas. Int J Cancer 72:43-49, 1997
PubMed
2) Christiano AM, et al:Structural organization of the human type VII collagen gene (COL7A1), composed of more exons than any previously characterized gene. Genomics 21:169-179, 1994
PubMed
3) Peltonen S, et al:Alternative splicing of mouse alphal (XIII) collagen RNAs results in at least 17 different transcripts, predicting alphal (XIII) collagen chains with length varying between 651 and 710 amino acid residues. DNA Cell Biol 16:227-234, 1997
 
4) Nakamura T, et al:Fibulin-5/DANCE is essential for elastogenesis in vivo. Nature 415:171-175, 2002
PubMed
5) Loeys B, et al:Homozygosity for a missense mutation in fibulin-5 (FBLN5) results in a severe form of cutis laxa. Hum Mol Genet 11:2113-2118, 2002
 
6) Rosenbloom J, et al:Inhibition of proline hydroxylation does not inhibit secretion of tropoelastin by chick aorta cells. FEBS Lett 65:246-250, 1976
 
7) Fujimoto N, et al:Elastin peptides induce migration and terminal differentiation of cultured keratinocytes Via 67 kDa elastin receptor in vitro:67 kDa elastin receptor is expressed in the keratinocytes eliminating elastic materials in elastosis perforans serpiginosa. J Invest Dermatol 115:633-639, 2000
PubMed
8) Klement JF, et al:Targeted ablation of the abcc6 gene results in ectopic mineralization of connective tissues. Mol Cell Biol 25:8299-8310, 2005
PubMed
9) Brown EL, et al:Resistance to Lyme disease in decorin-deficient mice. J Clin Invest 107:845-852, 2001
PubMed
10) Shapiro SD:Mighty mice:transgenic technology"knocks out"questions of matrix metalloproteinase function. Matrix Biol 15:527-533, 1997
PubMed
11) Holmbeck K, et al:MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell 99:81-92, 1999
PubMed
P.80 掲載の参考文献
1) Janeway CA Jr:Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol 54:1-13, 1989
 
2) Lemaitre B, et al:The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 86:973-983, 1996
 
3) Steiner H, et al:Sequence and specificity of two antibacterial proteins involved in insect immunity. Nature 292:246-248, 1981
 
4) Ritonja A, et al:Primary structure of a new cysteine proteinase inhibitor from pig leucocytes. FEBS Lett 255:211-214, 1989
PubMed
5) Zanetti M, et al:Cathelicidins:a novel protein family with a common proregion and a variable C-terminal antimicrobial domain. FEBS Lett 374:1-5, 1995
 
6) Murakami M, et al:Cathelicidin anti-microbial peptide expression in sweat, an innate defense system for the skin. J Invest Dermatol 119:1090-1095, 2002
PubMed
7) Murakami M, et al:Postsecretory processing generates multiple cathelicidins for enhanced topical antimicrobial defense. J Immunol 172:3070-3077, 2004
PubMed
8) Lopez-Garcia B, et al:Anti-fungal activity of cathelicidins and their potential role in Candida albicans skin infection. J Invest Dermatol 125:108-115, 2005
PubMed
9) Ganz T, et al:Defensins. Natural peptide antibiotics of human neutrophils. J Clin Invest 76:1427-1435, 1985
PubMed
10) Schittek B, et al:Dermcidin:a novel human antibiotic peptide secreted by sweat glands. Nat Immunol 2:1133-1137, 2001
 
11) Gallo RL, et al:Syndecans, cell surface heparan sulfate proteoglycans, are induced by a proline-rich antimicrobial peptide from wounds. Proc Natl Acad Sci U S A 91:11035-11039, 1994
PubMed
12) Frohm M, et al:The expression of the gene coding for the antibacterial peptide LL-37 is induced in human keratinocytes during inflammatory disorders. J Biol Chem 272:15258-15263, 1997
PubMed

第4章 アトピー性皮膚炎

P.84 掲載の参考文献
1) Yoshie O, et al:Chemokines in immunity. Adv Immunol 78:57-110, 2001
PubMed
2) Lee GR, et al:Transgenic mice which overproduce Th2 cytokines develop spontaneous atopic dermatitis and asthma. Int Immunol 16:1155-1160, 2004
PubMed
3) Leung DY, et al:New insights into atopic dermatitis. J Clin Invest 113:651-657, 2004
PubMed
4) Tada Y, et al:Granulocyte/macrophage colony-stimulating factor inhibits IL-12 production of mouse Langerhans cells. J Immunol 164:5113-5119, 2000
PubMed
5) Fujita H, et al:Differential production of Th1-and Th2-type chemokines by mouse Langerhans cells and splenic dendritic cells. J Invest Dermatol 124:343-350, 2005
PubMed
6) Kakinuma T, et al:Thymus and activation-regulated chemokine in atopic dermatitis:serum thymus and activation-regulated chemokine level is closely related with disease activity. J Allergy Clin Immunol 107:535-541, 2001
PubMed
7) Hijnen D, et al:Serum thymus and activation-regulated chemokine (TARC) and cutaneous T cell-attractilg chmokine (CTACK) levels in allergic diseases:TARC and CTACK are disease-specific markers for atopic dermatitis. J Allergy Clin Immunol 113:334-340, 2004
 
8) Leung TF, et al:Serum concentration of macrophage-derived chemokine may be a useful inflammatory marker for assessing severity of atopic dermatitis in infants and young children. Pediatric Allergy and Immunol 14:296, 2003
PubMed
9) Wakugawa M, et al:CC chemokme receptor 4 expression on peripheral blood CD4+Tcells reflects disease activity of atopic dermatitis. J Invest Dermatol 117:188-196, 2001
 
10) Biedermann T, et al:Targeting CLA/E-selectin interactions prevents CCR4-mediated recruitment of human Th2 memory cells to human skin in vivo. Eur J Immunol 32:3171-3180, 2002
PubMed
11) Kakinuma T, et al:Increased serum cutaneous T cell-attracting chemokine (CCL27) levels in patients with atopic dermatitis and psoriasis vulgaris. J AIIergy Clin Immunol 111:592-597, 2003
PubMed
12) Hudak S, et al:Immune surveillance and effector functions of CCR10+skin homing T cels. J Immunol 169:1189-1196, 2002
 
P.88 掲載の参考文献
1) Nishiyama C, et al:Regulation of human FcεRI α-chain gene expression by multiple transcription factors. J Immunol 168:4546-4552, 2002
 
2) Walsh JC, et al:Cooperative and antagonistic interplay between PU.1 and GATA-2 in the specification of myeloid cell fates. Immunity 17:665-676, 2002
PubMed
3) Ito T, et al:Mast cells acquire monocyte-specific gene expression and monocyte-like morphology by overproduction of PU.1. J Immunol 174:376-383, 2005
PubMed
4) Yamaguchi M, et al:IgE enhances mouse mast cell FcεRI expression in vitro and in vivo:Evidence for a novel amplification mechanism in IgE-dependent reactions. J Exp Med 185:663-672, 1997
 
5) Hasegawa M, et al:Regulation of the human FcεRI α-chain distal promoter. J Immunol 170:3732-3738, 2003
 
6) Sandford AJ, et al:Localisation of atopy and β subunit of high-affinity IgE receptor (FcεRI) on chromosome 11q. Lancet 341:332-334, 1993
 
7) Shirakawa T, et al:Association between atopic asthma and a coding variant of FcεRIβ in a Japanese population. Hum Mol Genet 5:1129-1130, 1996
 
8) Nishiyama C, et al:Polymorphisms in the FcεRIβ promoter region affecting transcription activity:apossible promoter-dependent mechanism for association between FcεRIβ and atopy. J Immmol 173:6458-6464, 2004
 
9) Hasegawa M, et al:Anovel-66T/C polymorphism in FcεRI α-chain promoter affecting the transcription activity:possible relationship to allergic diseases. J Immunol 171:1927-1933, 2003
 
11) Suzuki M, et al:Recent developments in genetic study of allergic disease in the Japanese population. Allergology International 54:359-365, 2005
 
12) Tsunemi Y, et al:Eotaxin gene single nucleotide polymorphisms in the promoter and exon regions are not associated with susceptibility to atopic dermatitis, but two of them in the promoter region are associated with serum IgE levels in patients with atopic dermatitis. J Dermal Sci 29:222-228, 2002
PubMed
13) Walley AJ, et al:Gene polymorphism in Netherton and common atopic disease. Nat Genet 29:175-178, 2001
PubMed
14) Cookson WOCM, et al:Genetic linkage of childhood atopic detmatitis to psoriasis susceptibility loci. Nat Genet 27:372-373, 2001
 
15) Nishiyama C:Molecular mechanism of allergy-related gene regulation and hematopoietic stem cell development by transcription factors. Biosci Biotechnol Biochem (Review) 70:1-9, 2006
 
P.89 掲載の参考文献
10) 片山一朗:アトピーアレルギー<アトピー性皮膚炎>,. 西岡 清編:やさしい皮膚免疫学.医薬ジャーナル社,大阪,p50-61, 2002
 
P.94 掲載の参考文献
1) Thomas WR, et al:Characterization and immunobiology of house dust mite allergens. Int Arch Allergy Immunol 129:1-18, 2002
PubMed
2) Takai T, et al:Recombinant Der p l and Der f l exhibit cysteine protease activity but no serine protease activity. Biochem Biophys Res Commun 328:944-952, 2005
 
3) Takai T, et al:Analysis of the structure and allergenicity of recombinant pro-and mature Der p l and Der f 1:Major conformational IgE-epitopes blocked by prodomains. J AIlergy Clin Immunol 115:555-563, 2005
 
4) Takai T, et al:Recombinant Der p l and Der f l with in Vitro enzymatic activity to cleave human CD23, CD25, and alphal-antitrypsin, and in vivo IgE-eliciting activity in mice. Int Arch Alergy Immunol 137:194-200, 2005
 
5) Takai T, et al:Maturation of the activities of recombinant mite allergens Der p 1 and Der f 1, and its implication in the blockade of proteolytic activity. FEBS Lett 531:265-272, 2002
PubMed
6) Gough L, et al:The cysteine protease activity of the major dust mite allergen Der p 1 selectively enhances the immunoglobulin E antibody response. J EXp Med 190:1897-1902, 1999
PubMed
7) Shakib F, et al:Amite subversive:cleavage of CD23 and CD25 by Der p 1 enhances allergenicity. Immunol Today 19:313-316, 1998
 
8) Wan H, et al:Der p 1 facilitates transepithelial allergen delivery by disruption of tight junctions. J Clin Invest 104:123-133, 1999
PubMed
9) Miike S, et al:Human eosinophils are activated by cysteine proteases and release inflammatory mediators. J Allergy Clin Immunol 111:704-713, 2003
PubMed
10) Asokananthan N, et al:House dust mite allergens induce proinflammatory cytokines from respiratory epithelial cells:the cysteine protease allergen, Der p 1, activates protease-activated receptor (PAR)-2 and inactivates PAR-1. J Immunol 169:4572-4578, 2002
PubMed
11) Grunstein MM, et al:Proasthnatic effects and mechanisms of action of the dust mite allergen, Der p 1, in airway smooth muscle. J AIIergy Clin Immunol l 16:94-101, 2005
 
12) Kato T, et al:Cystatin A inhibits IL-8 production by keratinocytes stimulated with Der p 1 and Der f 1:Biochemical skin barrier against mite cysteine proteases. J AIIergy Clin lrnmunol 116:169-176, 2005
PubMed
13) Sakata Y, et al:The squamous cell carcinoma antigen 2 inhibits the cysteine proteinase activity of a major mite allergen, Der p 1. JBiol Chem 279:5081-5087, 2004
 
14) Sun G, et al:Interaction of mite allergens Der p3 and Der p9 with protease-activated receptor-2 expressed by lung epithelial cells. J Immunol 167:1014-1021, 2001
PubMed
15) Ogawa H, et al:Aspeculative view of atopic dermatitis:barrier dysfunction in pathogenesis. J Dermatol Sci 5:197-204, 1993
PubMed
P.99 掲載の参考文献
1) 厚生科学研究班:アトピー性皮膚炎治療ガイドライン2002 http://www.kyudai-derm.org/atopy/atopy.html
 
2) アトピー性皮膚炎治療ガイドライン作成委員会:日本皮膚科学会編「アトピー性皮膚炎治療ガイドライン」.日皮会誌 110:1099-1104, 2000
 
3) アトピー性皮膚炎治療ガイドライン改定委員会:日本皮膚科学会アトピー性皮膚炎治療ガイドライン2004改訂版.日皮会誌 114:135-142, 2004
 
4) FK506軟膏研究会:アトピー性皮膚炎におけるタクロリムス軟膏0.1%および0.03%の使用ガイダンス.臨皮 57:1217-1234, 2003
 
5) アトピー性皮膚炎治療問題委員会タクロリムス外用薬問題ワーキンググループ:タクロリムス軟膏 (プロトピック軟膏) 使用中およびこれから使用される患者さんへ.日皮会誌 113:2078-2083, 2003
 
6) Ellis C, et al:International Consensus Conference on Atopic Dermatitis II (ICCAD H):clinical update and current treatment strategies. Br J Dermatol 148 (suppl 63):3-10, 2003
 
7) Hanifin JM, et al:Guidelines of care for atopic dermatitis. J Am Acad Dermato l 50:391404, 2004
 
8) アトピー性皮膚炎-よりよい治療のためのEvidence-based Medicine (EBM) とデータ集- http://www.kyudai-derm.org/atopy_ebm/index.html
 
P.102 掲載の参考文献
1) 川島 眞ほか:アトピー性皮膚炎の診療に対する患者の認識についてのアンケート調査 (第1報).臨床皮膚科 55 (2):113-119, 2001
 
2) 日本皮膚科学会,学術委員会,アトピー性皮膚炎不適切治療健康被害実態調査委員会:アトピー性皮膚炎における不適切治療による健康被害の実態調査 (最終報告).日本皮膚科学会雑誌 110 (7):1095-1098, 2000
 
3) 日本皮膚科学会,アトピー性皮膚炎治療ガイドライン改訂委員会:日本皮膚科学会アトピー性皮膚炎治療ガイドライン 2004改訂版.日本皮膚科学会雑誌 114 (2):135-142, 2004
 
4) 越後岳士ほか:脱ステロイド療法にて増悪後,入院治療を行ったアトピー性皮膚炎患者の分析.日本皮膚科学会雑誌 112 (11):1475-1479, 2002
 
5) 五十嵐敦之:脱ステロイド療法をどう評価するか.アレルギー.免疫 8 (11):1274-1278, 2001
 
6) 清水良輔:脱ステロイド療法の総括-方法と限界.臨床皮膚科 52 (5増):103-107, 1998
 
7) 玉置昭治:脱ステロイドの対象と方法と限界.日本皮膚科学会雑誌 107 (13):1686-1688, 1997
 
P.106 掲載の参考文献
1) Koch P, et al:Erythemanlultiforme-like, urticarial papular and plaque eruptions from bufexamac:report of 4 cases. Contact Dermatitis 31:97-101, 1994
PubMed
2) 順毛直弥ほか:ブフェキサマクによるacute generalized exanthematous pustulosisの1例.臨皮 56:313-316, 2002
 
3) Kranke B, et al:Epidemiological significance of bufexamac as afrequent and relevant contact sensitizer. Contact Dermatitis 36:212-215, 1997
 
4) Kitagaki H, et al:Repeated elicitation of contact hypersensitivity induces a shift in cutaneous cytokine milieu from a T helper cell type l to a T helper cell type 2 profile. J Immunol 159:2484-2491, 1997
 
5) Kitagaki H, et al:Distinct in Vivo and in Vitro cytokine profiles of draining lymph node cells in acute and chronic phases of contact hypersensitivity:importance of type 2 cytokine-rich cutaneous milieu for the development of an early-type response in the chronic phase. J Immunol 163:1265-1273, 1999
PubMed
6) Shiohara T, et al:Animal models for atopic dermatitis:Are they relevant to human disease? J Dermatol Sci (in press)
 
7) Yazdanbakhsh M, et al:Allergy, parasites, and the hygiene hypothesis. Science 296:490-494, 2002
PubMed
P.109 掲載の参考文献
1) Bock SA, et al:Double-blind, placebo-controlled food challenge (DBPCFC) as an office procedure:a manual. J Allergy Clin Immmol 82:986-997, 1988
 
2) Sampson HA, et al:Food hypersensitivity and atopic dermatitis:evaluation of 113 patients. J Pediatr 107:669-675, 1985
PubMed
3) Burks AW, et al:Atopic dermatitis:clinical relevance of food hypersensitivity reactions. J Pediatr 113:447-451, 1988
PubMed
4) Niggemann B, et al:Outcome of double-blind, placebo-controlled food challenge tests in 107 children with atopic dermatitis. Clin Exp Allergy 29:91-96, 1999
PubMed
5) Chandra RK, et al:Influence of maternal diet during lactation and use of formula feeds on development of atopic eczema in high risk infants. BMJ 299:228-230, 1989
PubMed
6) Hoare C, et al:Systematic review of treatments for atopic eczema. Health Technol Assess 4:1-191, 2000
PubMed
7) Atherton DJ, et al:Adouble-blind controlled crossover trial of an antigen-avoidance diet in atopic eczema. Lancet 8061:401-403, 1978
 
8) Lever R, et al:Randomised controlled trial of advice on an egg exclusion diet in young children with atopic eczema and sensitivity to eggs. Pediatr Allergy Immunol 9:13-19, 1998
 
9) Neild VS, et al:Egg and milk exclusion diets in atopic eczema. Br J Dermatol 114:117-123, 1986
PubMed
10) Mabin DC, et al:Controlled trial of a few foods diet in severe atopic dermatitis. Arch Dis Child 73:202-207, 1995
PubMed
11) Munkvad M, et al:Antigen-free diet in adult patients with atopic dermatitis. A double-blind controlled study. Acta Derm Venereol 64:524-528, 1984
PubMed
12) Zeiger RS, et al:The development and prediction of atopy in high-risk children:follow-up at age seven years in a prospective randomized study of combined maternal and infant food allergen avoidance. J Allergy Clin Irmunol 95:1179-1190, 1995
 
13) Herrmann ME, et al:Eur J Pediatr 155:770-774, 199614) Falth-Magnusson K, et al:Allergy prevention by maternal elimination diet during late pregnancy-a 5-year follow-up of a randomized study. J Allergy Clin Immunol 89:709-713, 1992
 
15) Cant AJ, et al:Effect of maternal dietary exclusion on breast fed infants with eczema:two controlled studies. Br Med J (Clin Res Ed) 293:231-233, 1986
PubMed
16) Hide DW, et al:Allergen avoidance in infancy and allergy at 4 years of age. Allergy 51:89-93, 1996
PubMed
17) Hattevig G, et al:Effect of maternal avoidance of eggs, cow:s milk and fish during lactation upon allergic manifestations in infants. Clin Exp Allergy 19:27-32, 1989
 
18) Hattevig G, et al:Effects of maternal dietary avoidance during lactation on allergy in children at 10 years of age. Acta Paediatr 88:7-12, 1999
PubMed

第5章 接触皮膚炎・蕁麻疹

P.114 掲載の参考文献
1) 伊藤正俊:皮膚テスト,宮地良樹ほか編:美容皮膚科学.南山堂,東京,p145-155, 2005
 
2) 佐々木和美:日用品皮膚障害の原因物質究明方法.MB Derma 46:66-73, 2005
 
3) Adachi A, et al:Metal Contact Allergy and Systemic Metal Allergy. J Enviro n Dermatol 12:1-8, 2005
 
4) 関東裕美ほか:ダーマボンドによる接触皮膚炎症候群.皮病診療 27:1035-1038, 2005
 
5) 関東裕美ほか:接触皮膚炎-美白剤による症例-.皮病診療 27:885-888, 2005
 
6) 宮川真輝ほか:カシューナッツシエルオイルによる接触皮膚炎の1例.臨皮 59:721-723, 2005
 
7) Kanto H, et al:A case of sandal dermatitis induced by cashew nut oil. J Envirom Dermatol 12:89-95, 2005
 
P.119 掲載の参考文献
1) Nutter AF:Contact urticaria to rubber. Br J Dermatol 101:597, 1979
PubMed
2) Beezhold DH, et al:Latex allergy can induce clinical reactions to specific foods. Clin Exp Allergy 26:416-422, 1996
PubMed
3) Ortolani C, et al:Comparison of results of skin prick test (with fresh foods and commercial food extracts) and RAST in 100 patients with oral allergy syndrome. J AIIergy Clin Immunol 83:683-690, 1989
PubMed
4) 冨高晶子ほか:栗摂取によりアナフィラキシーを呈したラテックスアレルギーの4例.アレルギー 49:327-334, 2000
Medical*Online
5) 冨高晶子ほか:ラテックスアレルギー30例の重症度と特異 IgE抗体,皮膚テストの関連性.日皮アレルギー会誌 7:28-35, 1999
Medical*Online
6) 松永佳世子:プリックテストのすすめ.日臨皮医会誌 63:54-58, 2000
 
7) Yagami T, et al:Plant defense-related enzymes as latex antigens. J Allergy Clin Immunol 101:379-385, 1998
PubMed
8) Blanco C, et al:Class I chitinases as potential panallergens involved in the latex-fruit syndrome. J Allergy Clin Immunol 103:507-513, 1999
 
9) Amlot PL, et al:Oral allergy syndrome (OAS):Symptoms of IgE-mediated hypersensitivity to foods. Clin Allergy 17:33-42, 1987
PubMed
10) Yagami T:Features and Mode of Action of Cross-reactive Plant Alergens Relevant to Latex-fruit Syndrome. Food and Agricultural Immunology 14:241-253, 2002
 
11) Breiteneder H, et al:Molecular and biochemical classification of plant-derived food allergens. Allergy Clin Irmunol 106:27-36, 2000
PubMed
12) Valenta R, et al:Profilins constitute a novel family of functional plant pan-allergens. J Exp Med 175:377-385, 1992
PubMed
P.123 掲載の参考文献
1) 秀 道広ほか:蕁麻疹.血管性浮腫の治療ガイドライン.日本皮膚科学会雑誌 115:703-715, 2005
 
2) 新見直正ほか:蕁麻疹,玉置邦彦,塩原哲夫編:皮膚免疫ハンドブック改訂2版.中外医学社,東京,p206-214, 2005
 
3) 猪又直子ほか:I型アレルギーによる蕁麻疹とその対策. MB Derma 105:15-27, 2005
 
4) Fukunaga A, et al:Responsiveness to autologous sweat and serum in cholinergic urticaria classifies its clmical subtypes. J Allergy Clin Immunol 116:397-402, 2005
 
5) Kaplan AP:Chronic uiticaria and Angioedema. N Engl J Med 346:175-179, 2002
PubMed
6) 小豆澤宏明:症候としての蕁麻疹-膠原病と症候群-.MB Derma 105:7-13, 2005
 
7) Sanada S, et al:The effectiveness of montelukast for the treatment of anti-histamine-resistant chronic urticaria. Arch Dermatol Res 297:134-138, 2005
PubMed
8) 秀 道広:蕁麻疹.アレルギー.免疫 12:1223-1228, 2005
 

第6章 自己免疫性水疱症

P.126 掲載の参考文献
1) Amagai, M:Pemphigus, J. Bolognia et al, editors:Dermatology. Harcourt Health Sciences, London, 449-462, 2003
 
2) Amagai M, et al:Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. Cell 67:869-877, 1991
PubMed
3) Amagai M, et al:Use of autoantigen-knockout mice in developing an active autoimmune disease model for pemphigus. J Clin Invest 105:625-631, 2000
PubMed
4) Tsunoda K, et al:Induction of pemphigus phenotype by a mouse monoclonal antibody against the amino-terminal adhesive interface of desmoglein 3. J Immunol 170:2170-2178, 2003
PubMed
5) Aoki-Ota M, et al:Tolerance induction by the blockade of CD40/CD154 interaction in pemphigus vulgaris mouse model. J Invest Dermatol 126:105-113, 2006
 
P.130 掲載の参考文献
1) Hashimoto T:Immunopathology of IgA pemphigus. Clin Dermatol 19:683-689, 2001
 
2) Nishikawa T, et al:Dermatoses with intraepidermal IgA deposits. Clin Dermatol 18:315-318, 2000
PubMed
3) Yasuda H, et al:Subcomeal pustular dermatosis type of IgA pemphigus:demonstration of autoantibodies to desmocollin-1 and clinical review. Br J Dermatol 143:144-148, 2000
 
4) Robinson ND, et al:The new pemphigus variants. J Am Acad Derniatol 40:649-671, 1999
PubMed
5) Hashimoto T, et al:Intercellular IgA dermatosis with clinical features of subcorneal pustular dermatosis. Arch Dermatol 123:1062-1065, 1987
PubMed
6) Tagami H, et al:Subcorneal pustular dermatosis with vesiculo-bullous eruption. Demonstration of subcorneal IgA deposits and a leukocyte chemotactic factor. Br J Dermatol 109:581-587, 1983
 
7) Huff JC, et al:Intraepidenmal neutrophilic IgA dermatosis. N Engl J Med 313:1643, 1985
PubMed
8) Ishii K, et al:Characterization of autoantibodies in pemphigus using antigen-specific enzyme-linked immunosorbent assays with baculovirus-expressed recombinant desmogleins. J Immunol 159:2010-2017, 1997
PubMed
9) Ebihara T, et al:Autoantigens for IgA anti-intercellular antibodies of intercellular IgA vesiculopustular dermatosis. J Invest Dermatol 97:742-745, 1991
PubMed
10) Hashimoto T, et al:Human desmocollin 1 (Dsc1) is an autoantigen for the subcorneal pustular dermatosis type of IgA pemphigus. J Invest Dermatol 109:127-131, 1997
PubMed
11) Hashimoto T, et al:Detection of IgA autoantibodies to desmogleins by an enzyme-linked immunosorbent assay:The presence of new minor subtypes of IgA pemphigus. Arch Dermatol 137:735-738, 2001
PubMed
12) Karpati S, et al:Identification of desmoglein 1 as autoantigen in a patient with intraepidermal neutrophilic IgA demiatosis type of IgA pemphigus. Exp Dermatol 9:224-228, 2000
 
13) Prost C, et al:IgA autoantibodies bind to pemphigus vulgaris antigen in a case of intraepidermal neutrophilic IgA dermatosis. J Am Acad Dermatol 25:846-848, 1991
 
14) Wang J, et al:Nonsecretory IgA1 autoantibodies targeting desmosomal component desmoglein 3 in intraepidermal neutrophilic IgA dermatosis. Am J Pathol 150:1901-1907, 1997
PubMed
15) Ishii N, et al:Immunolocalization of target autoantigens in IgA pemphigus. Clin Exp Dermatol 29:62-66, 2004
PubMed
P.134 掲載の参考文献
1) Tanaka T, et al:Comparison of molecularly cloned bullous pemphigoid antigen to desmoplakin I confirms that they defme a new family of cell adhesion junction plaque proteins. J Biol Chem 266:12555-12559, 1991
PubMed
2) Diaz LA, et al:Isolation of a human epidermal cDNA corresponding to the 180-kD autoantigen recognized by bullous pemphigoid and herpes gestationis sera. Immunolocalization of this protein to the hemidesmosome. J Clin Invest 86:1088-1094, 1990
 
3) Guo L, et al:Gene targeting of BPAG1:abnormalities in mechanical strength and cell migration in stratified epithelia and neurologic degeneration. Cell 81:233-243, 1995
PubMed
4) Liu Z, et al:A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. J Clin Invest 92:2480-2488, 1993
 
5) Lazarova Z, et al:Passive transfer of antilaminin 5 antibodies induces subepidermal blisters in neonatal mice. J Clin Invest 98:1509-1518, 1996
PubMed
P.138 掲載の参考文献
1) Collier PM, et al:Adult linear IgA disease and Chronic bullous disease of childhood:the association with human lymphocyte antigens cw7, B8, DR3 and tumour n
 
2) Lawley TJ, et al:Small intestinal biopsies and HLA types in dermatitis heretiformis patients with granular andkmear IgA skm deposits. J Invest Dermatol 74:9-12, 1980
 
3) Wojnarowska F, et al:Chronic bullous disease of childhood, childhood cicatricial pemphigoid, and linear IgA disease of adults. A comparative study demonstrating clinical and immunopathologic overlap. J Am Acad Dermatol 19:792-805, 1988
 
4) Guide SV, et al:Linear IgA bullous dermatosis. Clin Dermatol 19:719-27, 2001
 
5) Salmhofer W, et al:UV light-induced Inear IgA dermatosis. J Am Acad Dermatol 50:109-115, 2004
 
6) van der Waal RI, et al:Linear IgA bullous dermatosis in a patient with renal cell cartinoma. Br J Dermatol 144:870-873, 2001
 
7) Reunala TL:Dermatitis herpetiformis. Clin Dermatol 19:728-736, 2001
 
8) Shibahara M, et al:Dermatitis herpetiformis in Japan:an update. Dermatology 204:37-42, 2002
PubMed
9) Beutner EH, et al:Sensitivity and specificity of IgA-class antiendomysial antibodies for dermatitis herpetiformis and fmdings relevant to their pathogenic significance. J Am Acad Dermatol 15:464-473, 1986
 
10) Nicolas ME, et al:Dermatitis heipetiformis. Int J Dermatol 42:588-600, 2003
PubMed
11) Dieterich W, et al:Antibodies to tissue transglutaminase as serologic markers in patients with dermatitis heipetiformis. J Invest Dermatol 113:133-136, 1999
PubMed
12) Rose C, et al:Circulating autoantibodies to tissue transglutaminase differentiate patients with dermatitis herpetiformis from those with linear IgA disease. J Am Acad Dermatol 41:957-961, 1999
PubMed
ecrosis factor influences disease expression. Br J Dermatol 141:867-875, 1999
 
P.141 掲載の参考文献
1) Anhalt GJ, et al:Para neoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med 323:1729-1735, 1990
 
2) Amagai M, et al:Antibodies against desmoglein 3 (pemphigus vulgaris antigen) are present in sera from patients with paraneoplastic pemphigus and cause acantholysis in vivo in neonatal mice. J Clin Invest 102:775-782, 1998
PubMed
3) Nousari HC, et al:The mechanism of respiratory failure in paraneoplastic pemphigus. N Engl J Med 340:1406-1410, 1999
PubMed
4) 橋本 隆:腫瘍随伴性天疱瘡 (paraneoplastic pemphigus:PNP). 日皮会誌 111:1195-1203, 2001
 
5) Anhalt GJ:Paraneoplastic pemphigus. Adv Dermatol 12:77-96, 1997
PubMed
6) Kim SC, et al:cDNA cloning of the 210-kDa paraneoplastic pemphigus antigen reveals that envoplakin is a component of the antigen complex. J Invest Dermatol 109:365-369, 1997
PubMed
7) Ruhrberg C, et al:Periplakin, a novel component of cornified envelopes and desmosomes that belongs to the plakin family and forms complexes With envoplakin. J Cell Biol 139:1835-1849, 1997
 
8) Proby C, et al:Human autoantibodies against HD 1/plectin in paraneoplastic pemphigus. J Invest Dermatol 112:153-156, 1999
 
9) Hashimoto T, et al:Characterization of paraneoplastic pemphigus autoantigens by immunoblot analysis. J Invest Dermatol 104:829-834, 1995
PubMed
10) Ishii K, et al:Characterization of autoantibodies in pemphigus using antigen-specific ELISAs with baculovirus-expressed recombinant desmogleins. J Immunol 159:2010-2017, 1997
PubMed
11) Amagai M, et al:Usefulness of enzyme-linked Immunosorbent assay (ELISA) using recombinant desmogleins 1 and 3 for serodiagnosis of pemphigus. Br J Dermatol 140:351-357, 1999
PubMed
12) Fujimoto W, et al:Paraneoplastic pemphigus associated with Castleman:s disease and asymptomatic bronchiolitis obliterans. Eur J Dermatol 12:355-359, 2002
PubMed
13) Jansen T, et al:Paraneoplastic pemphigus with clinical features of erosive lichen planus associated with Castleman:s tumor. Dermatology 190:245-250, 1995
PubMed

第7章 膠原病

P.145 掲載の参考文献
1) Lipsky PE:Systemic lupus erythematosus:an autoimmune disease of B cell hyperactivity. Nat Immunol 2:764-766, 2001
PubMed
2) Shlomchik MJ, et al:From T to B and back again:positive feedback in systemic autoimmune disease. Nat Rev Immunol l:147-153, 2001
 
3) Matsumoto I, et al:Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme. Science 286:1732-1735, 1999
 
4) Agematsu K, et al:CD27:a memory B-cell marker. Immunol Today 21:204-206, 2000
PubMed
5) Sato S, et al:Altered blood B lymphocyte homeostasis in systemic sclerosis:expanded naive B cells and diminished but activated memory B cells. Arthritis Rheum 50:1918-1927, 2004
 
6) Sato S, et al:Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis. Mol Immunol 41:1123-1133, 2004
PubMed
7) Saito E, et al:CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. J Clin Invest 109:1453-1462, 2002
PubMed
8) Silverman GJ, et al:Rituximab therapy and autoimmune disorders:prospects for anti-B cell therapy. Arthritis Rheum 48:1484-1492, 2003
PubMed
9) Edwards JC, et al:Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) 40;205-211, 2001
PubMed
10) Looney RJ, et al:Bcell depletion as a novel treatment for systemic lupus eiythematosus:aphase I/H dose-escalation trial of rituximab. Arthritis Rheum 50:2580-2589, 2004
 
P.148 掲載の参考文献
1) Lehmann P, et al:Experimental reproduction of skin lesions in lupus erythematosus by UVA and UVB radiation. J Am Acad Dermatol 221:181-187, 1990
 
2) Furukawa F, et al:Photosensitivity in cutaneous lupus erythematosus:lessons from mice and men. J Dermatol Sci 33:81-89, 2003
 
3) 片山一朗ほか:光線テストで皮疹が誘発されたエリテマトーデス症例.Visual Demlatol 2:466-467, 2003
 
4) Weston WL:Significance and character of SS-A (Ro) and SS-B (La) antigens. J Invest Dermatol 84:85, 1985
 
5) Pablos JI., et al:Keratinocyte apoptosis and p53 expression in cutaneous lupus and dermatomyositis. J Pathol 188:63-68, 1999
 
6) Werth VP, et al:Photosensitivity in Rheumatic diseases. J Invest Dermatol Sym Proc 9:57-63, 2004
 
7) Millard TP:Cutaneous lupus erythematosus. Kuhn. Lehmann Ruzicka Ed. Springer Publishers, Verlag Berlin Heidelberg New York, 15:205-220, 2004
 
8) Furukawa F, et al:Keratinocytes from patients with lupus erythematosus show enhanced cytotoxicity to ultraviolet radiation and to antibody-mediated cytotoxicity. Clin Exp Immunol 118:164-170, 1999
PubMed
9) Yoshimasu T, et al:Comparison of 60 and 52 kDa SS-AIRo antibodies in the pathogenesis of cutaneous lupus erythematosus. J Dermatol Sci 29:35-41, 2002
 
10) Werth VP, et al:IL-12 completely blocks ultraviolet-induced secretion of tumor necrosis factor a from cultured skm fibrob-lasts and keratinocytes. J Invest Dermatol 120:116-122, 2003
 
11) Gerl V, et al:The intracelular 52-kd Ro/SSA autoantigen in ker-atinocytes is up-regulated by tumor necrosis factor a via tumor necrosis factor receptor 1. Arthritis Rheum 152:531-538, 2005
 
12) Kuhn A, et al:Lupus erythematosus tumidus. Arch Dermatol 136:1033-1041, 2000
PubMed
13) Dekle CL, et al:Lupus tumidus. J Am Acad Dermatol 41:250-253, 1999
PubMed
14) Kuhn A, et al:Phototesting in Lupus Eiythematosus Tumidus-Review of 60 Patients. Photochem Photobiol 73:532-536, 2001
PubMed
15) Yoshimasu T, et al:Discoid lupus erythematosus (DLE)-like lesion induced by uracil-tegafur (UFT). Eur J Dermatol 11:54-57, 2001
PubMed
16) Yoshimasu T, et al:Susceptibility of T cell receptor-α chain knock-out mice to ultraviolet B light and fluorouracil:anovel model for drug-ilduced cutaneous lupus erythematosus. Clin Exp Immunol 136:245-254, 2004
 
17) Nishide T, et al:Cytokine profiles of skin lesions in murine lupus models. J Dermatol Sci (in press)
 
P.153 掲載の参考文献
1) Ihn H, et al:Blockade of endogenous transforming growth factor B signaling Prevents up-regulated collagen synthesis in scleroderma fibroblasts:association with increased expression of transforming growth factor β receptors. Arthritis Rheum 44:474480, 2001
 
2) Kubo M, et al:Up-regulated expression of transforming growth factor β receptors in dermal fibroblasts in skin sections from patients with localized scleroderma Arthritis Rheum 44:731-734, 2001
 
3) Ihm H, et al:Increased phosphorylation of transcription factor Spl in scleroderma fibroblasts:association with increased expression of type I collagen gene. Arthritis Rheum 43:2240-2247, 2000
 
4) Ihn H, et al:Transcriptional regulation of the human α2 (1) collagen gene:combined action of upstream stimulatory and inhibitory cisacting elements, J Biol Chem 271:26717-26723, 1996
 
5) Ihn H, et al:Oncostatin M stimulates transcription of the human α2 (1) collagen gene Via the Sp 1/Sp3-binding site. J Biol Chem 272:24666-24672, 1997
 
6) Ihn H, et al:Sp3 is a transcriptional activator of the human α2 (1) collagen gene. Nucleic Acids Res 25:3712-3717, 1997
 
7) Ihn H, et al:Oncostatin M stimulates the growth of dermal fibroblasts via a mitogen-activated protein kinase-dependent pathway. J Immunol 165:2149-2155, 2000
 
8) Ihn H, et al:IL-4 up-regulates the expression of tissue inhibitor of metalloproteinase-2 in dermal fibroblasts via the p38 mitogen-activated protein kinase-dependent pathway. J Immunol 168:1895-1902, 2002
PubMed
9) Ihn H, et al:Increased phosphorylation and activation of mitogen-activated protein kinase p38 in scleroderma fibroblasts. J Invest Dermatol 125:247-255, 2005
PubMed
10) Igarashi A, et al:Significant correlation between connective tissue growth factor gene expression and skin sclerosis in tissue sect, ions from patients with systemic sclerosis. J Invest Dermatol 105:280-284, 1995
 
11) Jinnin M, et al:α2 (1) collagen gene regulation by protein kinase C signaling in human dermal fibroblasts. Nucleic Acids Res 33:1337-1351, 2005
 
12) Yamane K, et al:Increased transcriptional activities of transforming growth factor-Breceptors in scleroderma fibroblasts. Arthritis Rheum 46:2421-2428, 2002
 
13) Yamane K, et al:Epidermal growth factor up-regulates expression of transforming growth factor-B receptor type H in human dermal fibroblasts by phosphoinositide 3-kinase/Akt signaling pathway:Resistance to epidermal growth factor stimulation in scleroderma fibroblasts. Arthritis Rheum 48:1652-1666, 2003
 
14) Yamane K, et al:Antagonistic effects of TNF-a on TGF-B signaling through down-regulation of TGF-Breceptor type H in human dermal fibroblasts. J Immunol 171:3855-3862, 2003
 
15) Asano Y, et al:Impaired Smad7-Smurf-mediated negative regulation of TGF-Bsignaling in scleroderma fibroblasts. J Clin hnvest 113:253-264, 2004
 
16) Asano Y, et al:Increased expression levels of integrin αvβ 5 on sclerodenma fibroblasts. Am J Pathol 164:1275-1292, 2004
 
17) Mimura Y, et al:Constitutive thrombospondin-1 overexpression contributes to autocrine transforming growth factor-B signaling in cultured scleroderma fibroblasts. Am J Pathol 166:1451-1463, 2005
 
P.156 掲載の参考文献
1) 小川法良ほか:シェーグレン症候群.総合臨床 51:2149-2154, 2002
Medical*Online
2) 臼田俊和:Sjogren症候群,玉置邦彦ほか:最新皮膚科学大系9膠原病非感染性肉芽腫.中山書店,東京,142-154, 2002
 
3) 片山-朗:シェーグレン症候群の皮膚症状.皮膚科の臨床 39:285-291, 1997
 
4) 麻生和雄:老人性乾皮症型シェーグレン症候群.日皮会誌 103:797-804, 1993
 
5) 宮川幸子:環状紅斑の病態と分類-20世紀の総括-.西日皮膚 63:3-7, 2001
 
6) 山本純照ほか:Sjogren症候群に伴う環状紅斑と抗SS-A/Ro 抗体及び抗SS-B/La抗体との関連性の経時的観察.日皮会誌 111:2087-2092, 2001
 
7) 塚崎直子ほか:Sjogren症候群患者の光線過敏症状.皮膚病診療 23:287-290, 2001
 
8) 高橋亜由美ほか:急性の発熱と皮疹を主訴としたsubclinical Sjogren症候群の1例.臨床皮膚科 53:728-731, 1999
 
9) 江内田智子ほか:発熱と浸潤性紅斑を繰り返し生じた Sjogren症候群.臨床皮膚科 57:890-892, 2003
 
10) 石川 治:しもやけとシェーグレン症候群.Medical Practice 18:498, 2001
Medical*Online
11) 伊藤正寛:高γグロブリン血症性紫斑.別冊 日本臨床領域別症候群 31 (上):389-391, 2000
 
12) 森 健-ほか:下腿潰瘍を生じシェーグレン症候群を合併した高ガンマグロブリン血症性紫斑.皮膚科の臨床 36:1685-1689, 1994
 
13) Katz J, et al:Drug Allergy in Sjogren:s syndrome. Lancet 337:239, 1991
PubMed
P.160 掲載の参考文献
1) Hughes GRV, et al:The antiphospholipid syndrome:Ten years on. Lancet 342:341-344, 1993
 
2) Galli M, et al:Anti-B 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood 102:2717-2723, 2003
 
3) Alegre VA, et al:Skin lesions associated with circulating lupus anticoagulant. Br J Dermatol 120:419-429, 1989
PubMed
4) Wilson WA, et al:International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome:report of an international workshop. Arthritis Rheum 42:1309-1311, 1999
PubMed
5) Atsumi T, et al:Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. Arthritis Rheum 43:1982-1993, 2000
PubMed
6) Pierangeli SS, et al:Antiphospholipid antibodies from antiphospholipid syndorome patients activate endothelial cells in Vitro and in vivo. Circulation 99:1997-2002, 1999
 
7) Amengual O, et al:Specificities, properties, and clinical significance of antiprothrombin antibodies. Arthritis Rheum 48:886-895, 2003
PubMed
8) Gibson GE, et al:Antiphospholipid syiidrome and the skn. J Am Acad Dermatol 36:970-982, 1997
 
9) Hasegawa M, et al:Autoantibodies against phosphatidylserine-prothrombin complex in patients with systemic sclerosis. Ann Rheum Dis 63:1514-1517, 2004
PubMed
10) Sato S, et al:Antiphospholipid antibody in localised sclerodemla. Ann Rheum Dis 62:771-774, 2003
PubMed
11) Asherson RA, et al:Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients. Medicine 77:195-207, 1998
PubMed
P.164 掲載の参考文献
1) Nishikai M, et al:Heterogeneity of precipitating antibodies in polymyositis and dermatomyositis. Characterization of the Jo-1 antibody system. Arthritis Rheum 23:881-888, 1980
PubMed
2) Targoff IN:Laboratory testing in the diagnosis and management of idiopathic inflammatory myopathies. Rheum Dis Clin North Am 28:859-890, viii, 2002
PubMed
3) Yoshida S, et al:The precipitating antibody to an acidic nuclear protein antigen, the Jo-1, in connective tissue dis-eases. A marker for a subset of polymyositis with interstitial pulmonary fibrosis. Arthritis Rheum 26:604-611, 1983
 
4) Love LA, et al:Anew approach to the classification of idiopathic inflammatory myopathy:myositis-specific autoanti-bodies define useful homogeneous patient groups. Medicine (Baltimore) 70:360-374, 1991
 
5) Marguerie C, et al:Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes. Q J Med 77:1019-1038, 1990
PubMed
6) Hirakata M, et al:Interstitial lung disease in polymyositis and dermatomyositis. Curr Opin Rheumatol 12:501-508, 2000
PubMed
7) Sato S, et al:Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermato-myositis. Arthritis Rheum 52:1571-1576, 2005
 
8) Targoff IN, et al:Antibodies to glycyl-transfer RNA synthetase in patients with myositis and interstitial lung disease. Arthri-tis Rheum 35:821-830, 1992
 
9) Friedman AW, et al:Interstitial lung disease with autoanti-bodies against aminoacyl-tRNA synthetases in the absence of clinically apparent myositis. Semin Arthritis Rheum 26:459-467, 1996
 
10) Hirakata M, et al:Anti-.KS:identification of autoantibodies to asparaginyl-transfer RNA synthetase associated with intersti-tial lung disease. J Immunol 162:2315-2320, 1999
 
11) Sato S, et al:Clinical characteristics of Japanese patients with anti-PL7 (anti-threonyl-tRNA synthetase) autoantibodies. Clin Exp Rheumatol 23:609-615, 2005
PubMed
12) Howard OM, et al:Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature den-dritic cells. J Exp Med 196:781-791, 2002
 

第8章 感染症

P.168 掲載の参考文献
1) 荒田次郎:壊死性筋膜炎necrotizing fasciitisとその類症, 荒田次郎編:図解皮膚細菌感染症.田辺製薬,東京,p54-65, 1997
 
2) The working group on severe streptococcal infections:Defining the group A streptococcal toxic shock syndrome. JAMA 269:390-391, 1993
 
3) 清水可方:劇症型A群溶レン菌感染症.臨皮 49:26-30, 1995
 
4) Hasham S, et al:Necrotising fasciitis. BMJ 330:830-833, 2005
PubMed
5) 山崎修ほか:壊死性筋膜炎とその類症.第12回Lancefield レンサ球菌研究会抄録集:p20, 2003
 
6) Lille ST, et al:Necrotizing soft tissue infections:obstacles in diagnosis. J Am Coll Surg l 82:7-11, 1996
 
7) Elliott DC, et al:Necrotizing soft tissue infectons. Risk factors for mortality and strategies for management. Ann Surg 224:672-683, 1996
 
8) Singh G, et al:Necrotising infections of soft tissues-a clinical profile. Eur J Surg 168:366-371, 2002
PubMed
9) McHenry CR, et al:Determinants of mortality for necrotizing soft-tissue infections. Ann Surg 221:558-565, 1995
PubMed
10) Herwald H, et al:Mprotein, a classical bacterial virulence determinant, forms complexes with fibrinogen that induce vascular leakage. Cell 116:367-379, 2004
 
11) Konman TM, et al:Fatal case of toxic shock-like syndrome due to group C streptococcus associated with superantigen exotoxin. J Clin Microbiol 42:2866-2869, 2004
 
12) Reich HL, et al:Group B streptococcal toxic shock-like syndrome. Arch Dermatol 140:163-166, 2004
 
13) 古城八寿子ほか:Vibrio vulnificus感染症-診断と治療のフローチャートの試み-.日皮会誌 109:875-884, 1999
 
14) Chiang SR, et al:Vibrio vulnificus infection:clinical manifestation, pathogenesis, and antimicrobial therapy. J Microbiol Immunol Infect 36:81-88, 2003
PubMed
15) 立山直ほか:Aeromonas壊死性軟部組織感染症-本症重篤化機序についての一考察-.日皮会誌 110:815-829, 2000
 
16) Eke N:Fournier:s gangrene:Areview of 1726 cases. Br J Surg 87:718-728, 2000
 
P.171 掲載の参考文献
1) 望月 隆:Arthrodermabenhamiae感染症の現状.日皮会誌 115:1903-1905, 2005
 
2) Kawasaki M, et al:Two cases of tinea corporis by infection from a rabbit with Arthroderma benhamiae. 真菌誌 41:263-267, 2000
 
3) 望月 隆ほか:格闘技競技者間に流行しているTdrichophyton tonsurans感染症.臨皮 58:15-19, 2004
 
4) 川合さなえほか:柔道及び相撲部員に発症したTrichophy-ton.tonsuransによる白癬.日皮会誌 115:145-150, 2005
 
5) 白木祐美ほか:某大学柔道部のTrichophyton tonsurans感染症の集団検診結果とその対策.真菌誌 45:7-12, 2004
 
6) Makimura K, et al:Phylogenetic classification of Trichophg-ton mentagrophytes complex strains based on DNA sequences of nuclear ribosomal internal transcribed spacer l regions. J Clin Microbiol 36:2629-2633, 1998
 
7) Mochizuki T, et al:Rapid identification of Trichophyton tonsu. rans by PCR-RFLP analysis of ribosomal DNA regions. J Denmatol Sci 32:25-32, 2003
 
8) Kano R, et al:Phylogenetic analysis of 8 dermatophyte species using chitin synthase l gene sequences. Mycoses 40:411-414, 1997
 
9) Kanbe T, et al:Species-identification of dermatophytes Trichophyton, microsporum and Epidermophyton by PCR and PCR-RFLP targethlg of the DNA topoisomerase H genes. J Dermatol Sci 33:41-54, 2003
 
10) Jackson CJ, et al:Strain identification of Trichophyton rubrum by specific amplification of subrepeat elements in the ribosomal DNA nontranscribed spacer. J Clin Microbiol 38:4527-4534, 2000
PubMed
11) Gaedigk A, et al:Genetic heterogeneity in the rRNA gene locus of Trichophyton tonsurans. J Clin Microbiol 41:5478-5487, 2003
PubMed
12) 望月 隆:爪白癬の診断.爪真菌症診療マニュアル.MB Derma (in press)
 
13) Mochizuki T, et al:Anail drilling method suitable for the diagnosis of onychomycosis, J Dermatol 32:108-113, 2005
 
14) 甲野 健ほか:足爪真菌症内服治療に関するメタアナリシスの試み.臨床医薬 20:777-784, 2004
 
15) 福田知雄:外用抗真菌剤を用いた爪白癬の治療における歯科用ドリル併用の効果.日皮会誌 111:37-42, 2001
 
P.175 掲載の参考文献
1) Hirota K, et al:Prospective study on maternal, intrauterine, and perinatal infections with cytomegalovirus in Japart during 19761990. JMed Virol 37 (4):303-306, 1992
 
2) Drago F, et al:Cytomegalovirus infection in normal and immunocompromised humans. Dermatology 200 (3):189-195, 2000
PubMed
3) 森 康子ほか:ウイルスの持続感染,山本直樹 編:ウイルスを知る.羊土社,東京,p70-78, 1999
 
4) 南嶋洋一ほか:感染症とその検査法 サイトメガロウイルス 感染症.検査と技術 24 (7):227-230, 1996
 
5) Dauden E, et al:Mucocutaneous presence of cytomegalovirus associated with human immunodeficiency Virus infection:discussion regarding its pathogenetic role. Arch Dermatol 137 (4):443-448, 2001
PubMed
6) Ramdial PK, et al:Cytomegalovirus neuritis in perineal ulcers. J Cutan Pathol 29 (7):439-444, 2002
PubMed
7) Pariser RJ:Histologically specific skin lesions in disseminated cytomegalovirus infection. J Am Acad Dermatol 9 (6):937-946, 1983
PubMed
8) Kondo K, et al:Humancytomegalovirus latent infection of granulocyte-macrophage progenitors. Proc Natl Acad Sci USA 91 (25):11879-11883, 1994
 
9) Halm G, et al:Cytomegalovirus remains latent in a common precursor of dendritic and myeloid cells. Proc Natl Acad Sci USA 95 (7):3937-3942, 1998
 
10) Docke WD, et al:Cytomegalovirus reactivation and tumour necrosis factor. Lancet 343:268-269, 1994
PubMed
11) Fietze E, et al:Cytomegalovirus infection in transplant recipients. The role of tumor necrosis factor. Transplantation 58 (6):675680, 1994
 
12) Asadullah K, et al:Ahigh prevalence of cytomegalovirus antigenaemia in patients with moderate to severe chronic plaque psoriasis:an association with systemic tumour necrosis factor alpha overexpression. Br J Dermatol 141 (1):94-102, 1999
 
13) 岸本三郎:皮膚創傷治癒 そのメカニズムと治療.日皮会誌 113 (7):1087-1093, 2003
 
14) Asahara T, et al:Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 85 (3):221-228, 1999
PubMed
15) Swanson S, Feldinan PS:Cytomegalovirus infection initially diagnosed by skm biopsy. Am J Clin Pathol 87 (1):113-116, 1987
 

第9章 遺伝性皮膚疾患

P.178 掲載の参考文献
1) Akiyama M:The pathogenesis of severe congenital ichthyosis of the neonate. J Dermatol Sci 21:96-104, 1999
PubMed
2) Almilo T, et al:Identification and characterization of a novel ABCA subfamily member, ABCA12, located in the lamellar ichthyosis region on 2q34. Cytogenet Genome Res 98:169-176, 2002
 
3) Peelman F, et al:Characterization of the ABCA transporter subfamily:identification of prokaryotic and eukaryotic members, phylogeny and topology. J Mol Biol 325:259-274, 2003
PubMed
4) Yamano G, et al:ABCA3 is a lamellar body membrane protein in human lung alveolar type II cells. FEBS Lett 508:221-225, 2001
PubMed
5) Akiyama M, et al:Mutations in lipid transporter ABCA12 in harlequin ichthyosis and functional recovery by corrective gene transfer. J Clin Invest 115:1777-1784, 2005
PubMed
6) Akiyama M, et al:Characteristic morphologic abnormality of harlequin ichthyosis detected in amniotic nuid cells. J Invest Dermatol 102:210-213, 1994
 
7) Akiyama M, et al:Regional difference in expression of characteristic abnormality of harlequin ichthyosis in affected fetuses. Prenat Diagn 18:425-436, 1998
PubMed
8) Borst P, et al:Mammalian ABC transporters in health and disease. Annu Rev Biochem 71:537-592, 2002
PubMed
9) Shulenin S, et al:ABCA3 gene mutations in newboms with fatal surfactant deficiency. N Engl J Med 350:1296-1303, 2004
 
10) Lefevre C, et al:Mutations in the transporter ABCA12 are associated with lamellar ichthyosis type 2. Hum Mol Genet 12:2369-2378, 2003
PubMed
11) Akiyama M, et al:The clinical spectrum of nonbullous congenital ichthyosiform erythroderma and lamellar ichthyosis. Clin EXp Dermatol 28:235-240, 2003
PubMed
12) Akiyama M, et al:Prenatal diagnosis of harlequin ichthyosis by the examination of keratinized hair canals and amniotic fluid cells at 19 weeksl estimated gestational age. Prenat Diagn 19:167-171, 1999
 
13) Tsuji-Abe Y, et al:DNA-based prenatal exclusion of bullous congenital ichthyosiform erythroderma at the early stage, 10 to 11 weeks:of pregnancy, in two consequent siblings. J Am Acad Dermatol 51:1008-1011, 2004
PubMed
14) Choate KA, et al:Corrective gene transfer in the human skin disorder lamellar ichthyosis. Nat Med 2:1263-1267, 1996
PubMed
15) Freiberg RA, et al:Amodel of corrective gene transfer in X-linked ichthyosis. Hum Mol Genet 6:927-933, 1997
 
P.182 掲載の参考文献
1) 池田志斈:Darier病,玉置邦彦 編:最新皮膚大系7角化異常性疾患.中山書店,東京,160-167, 2002
 
2) 鈴木 裕:Ca(2+)ポンプの構造/機能連関および遺伝子 異常と細胞病態.生化学 75:1215-1224, 2003
 
3) Toyoshima C, et al:Crystal structure of the calcium pump of sarcoplasmic reticulum at 2. 6 A resolution. Nature 405:647-655, 2000
PubMed
4) Toyoshima C, et al:Structural changes in the calcium pump accompanying the dissociation of calcium. Nature 418:605-611, 2002
PubMed
5) Sakuntabhai A, et al:Mutations in ATP2A2, encoding a Ca2+ pump, cause Darier disease. Nat Genet 21:271-277, 1999
PubMed
6) Hovnanian A:Darier:s disease:from dyskeratosis to endoplasmic reticulum calcium ATPase deficiency. Biochem Bioph Res Co 322:1237-1244, 2004
 
7) Takahashi H, et al:Novel mutations of ATP2A2 gene in Japanese patients of Darier:s disease. J Dermatol Sci 26:169-172, 2001
PubMed
8) Sato K, et al:Distinct types of abnormality in kinetic properties of three Darier disease-causing sarco (endo) plasmic reticulum Ca2+-ATPase mutants that exhibit normal expression and high Ca2+transport activity. J Biol Chem 279:35595-35603, 2004
PubMed
9) Miyauchi Y, et al:(manuscript in preparation)
 
10) Ahn W, et al:Multiple effects of SERCA2b mutations associated with Darier:s disease. J Biol Chem 278:20795-20801, 2003
PubMed
11) Dode L, et al:Dissection of the Functional Differences between Sarco (endo) plasmic Reticulum Ca2+-ATPase (SERCA) 1and 21soforms and Characterization of Darier Disease (SERCA2) Mutants by Steady-state and Transient Kinetic Aiialyses J Biol Chem 278:47877-47889, 2003
 
12) Dhitavat J, et al:Impaired trafficking of the desmoplakins in cultured Darier's disease keratinocytes. J Invest Dermatol 121:1349-1355, 2003
PubMed
P.186 掲載の参考文献
1) Hu Z, et al:Mutations in ATP2C1, encoding a calcium pump, cause Hailey-Hailey disease. Nat Genet 24:61-65, 2000
PubMed
2) Behne MJ, et al:Human keratinocyte ATP2C1 localizes to the Golgi and controls Golgi Ca2+stores. J Invest Dematol 121:688-694, 2003
 
3) Leinonen PT, et al:Keratinocytes cultured from patients with Hailey-Hailey disease and Darier disease display distinct patterns of calcium regulation. Br J Dermatol 153:113-117, 2005
PubMed
4) Mayuzumi N, et al:Effects of Ultraviolet B irradiation, proinflammatory cytokines and raised extracellular calcium concentration on the expression of ATP2A2 and ATP2C1. Br JDermatol 152:697-701, 2005
PubMed
5) Mayuzumi N, et al:Effects of drugs and anticytokine antibodies on expression of ATP2A2 and ATP2C1 in cultured normal human keratinocytes. Br J Dermatol 152:920-924, 2005
PubMed
6) Ikeda S, et al:Successful management of Hailey-Hailey disease With potent topical steroid ointment. J Dermatol Sci 5:205-211, 1993
PubMed
7) Jitsukawa K, et al:Topical cyclosporine in chronic benign familial pemphigus (Hailey-Hailey disease). JAm Acad Dermatol 27:625-626, 1992
 
8) Aoki T, et al:1alpha, 24-dihydroxyvitamin D3 (tacalcitol) is effective against Hailey-Hailey disease both in vivo and in Vitro. Br J Dermatol 139:897-901, 1998
PubMed
9) Rabeni EJ, et al:Efifective treatment of Hailey-Hailey disease with topical tacrolimus. J Am Acad Dermatol 47:797-798, 2002
PubMed
10) Hunt MJ, et al:Vesiculobullous Hailey-Hailey disease:successful treatment with oral retinoid. Australas J Dermatol 37:196-198, 1996
PubMed
11) Kawada H, et al:Transcriptional regulation of ATP2C1 gene by Spl and YYI and reduced function of its promoter in Hailey-Hailey disease keratinocytes. J Invest Dermatol 124:1206-1214, 2005
 
12) Jang SI, et al:Loricrin expression in cultured human keratinocytes is controlled by a complex interplay between transcription factors of the Sp1, CREB, AP1, and AP2 families. J Biol Chem 277:42268-42279, 2002
PubMed
13) Lee JH, et al:The proximal promoter of the human transglutaminase 3 gene. J Biol Chem 271:4561-4568, 1996
 
14) Lopez-Bayghen E, et al:Transcriptional analysis of 5:-noncoding region of the human involucrin. J Biol Chem 271:512-520, 1996
PubMed
15) Liu LH, et al:Squamous cell tumors in mice heterozygous for anull allele of Atp2a2, encoding the sacro (endo) plasmic reticulum Ca2+-ATPase isoform 2 Ca2+pump. J Biol Chem 276:26737-26740, 2001
 
P.190 掲載の参考文献
1) Griffiths WAD, et al:Rook/Wilkinson/Ebling Textbook of Dermatology. 6th ed, vol 2, Blackwell Science, Oxford, 1483, 1998
 
2) Chavanas S, et al:Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome. Nat Genet 25:141-142, 2000
PubMed
3) Magert HJ, et al:LEKTI, a novel 15-domain type of human sele proteinase inhibitor. J Biol Chem 274:21499, 1999
 
4) Komatsu N, et al:Elevated stratum corneum hydrolytic activity in Netherton syndrome suggests an inhibitory regulation of desquamation by SPINK5-derived peptides. J Invest Dermatol 118:436, 2002
PubMed
5) Jayakumar A, et al:Expression of LEKTI domains 6-9:in the baculovirus expression system:recombinant LEKTI domains 6-9' inhibit tiypsin and subtilisin A. Protein Expr Purif 35:93-101, 2004
PubMed
6) Bitoun E, et al:LEKTI proteolytic processing in human primary keratinocytes, tissue distribution and defective expression in Netherton syndrome. Hum Mol Genet 12:2417-2430, Epub 2003 Jul 29,
 
7) Ishida-Yamamoto A, et al:LEKTI is localized in lamellar granules, separated from KLKs and KLK7, and is secreted in the extracellular spaces of the superficial stratum granulosum. J Invest Dermatol 124:360-366, 2005
 
8) Yousef GM, et al:The new human tissue kallikrein gene family:structure, function, and association to disease. Endocr Rev 22:184-204, 2001
PubMed
9) Ekholm IE, et al:Stratum comeum tryptic enzyme in normal epidermis:a missing link in the desquamation process? J Invest Dermatol 114:56-63, 2000
 
10) Komatsu N, et al:Quantification of human tissue kallikreins in the stratum comeum:dependence on age and gender. J Invest Dermatol 125:1182-1189, 2005
 
11) Komatsu N, et al:Quantification of Eight Tissue Kallikreins in the Stratum Corneum and Sweat. J Invest Dermatol:2006 (in press)
 
12) Komatsu N, et al:Multiple tissue kallikrein mRNA and protein expression in nonmal skin and skin diseases. Br J Dermatol 153:274-281, 2005
 
13) Caubet C, et al:Degradation of comeodesmosome proteins by two serine proteases of the kallikrein family, SCTE/KLK5/hK5 and SCCE/KLK7/hK7. J Invest Dermatol. 122:1235-1244, 2004
PubMed
14) Ya-Xian Z, et al:Number of cell layers of the stratum comeum in normal skin-relationship to the anatomical location on the body, age, sex and physical parameters. Arch Demiatol Res 291:555-559, 1999
 
15) Descargues P, et al:Spink5-deficient mice mimic Netherton syndrome through degradation of desmoglein 1 by epidermal protease hyperactivity. Nat Genet 2005 Jan; 37 (1):56-65, Epub 2005 Dec 26.
 
16) 小松奈保子:Netherton症候群とSPINK5.臨床皮膚科 57:51-58, 2003
 
17) Alam KS, et al:Expression and purification of a mutant human growth hormone that is resistant to proteolytic cleavage by thrombin, plasmin and human plasma in vitro. J Biotechnol 65:183-190, 1998
PubMed
P.193 掲載の参考文献
1) Fine JD, et al:Revised classification system for inherited epidermolysis bullosa:Report of the Second International Consensus Meeting on diagnosis and classification of epidermolysis bullosa. J Am Acad Dermatol 42:1051-1066, 2000
PubMed
2) Nakamura H, et al:Epidermolysis bullosa simplex associated with pyloric atresia is a novel clinical subtype caused by mutations in the plectin gene (PLEC1). J Mol Diagn 7:28-35, 2005
PubMed
3) Pfendner E, et al:Plectin gene mutations can cause epidermolysis bullosa with pyloric atresia. J Invest Dermatol 124:111-115, 2005
PubMed
4) Nobuhara, et al:The head domain of K5 binds to a dynin light chain, the cytoplasmic motor cargo complex, and might be involved in the distribution of keratin filaments and melanosomes, J Invest Demlatol 121:2003 (abstract)
 
5) Horiguchi, et al:Clinical heterogeneity of 1649delG mutation in the tail domain of keratin 5:a Japanese family with epidermolysis bullosa simplex with mottled pigmentation. J Invest Dermatol 125:83-85, 2005
PubMed
6) Gu LH, et al:Ausual frameshift and delayed termination codon mutation in keratin 5 causes a novel type of epidermolysis bullosa simplex with migratory circinate erythema. J Invest Dermatol 121:482-485, 2003
 
7) Kawasaki H, et al:Squamous cell carcinoma developing in a 12-year-old boy with nonHallopeau-Siemens recessive dystrophic epidermolysis bullosa. Br J Dermatol 148:1047-1050, 2003
 
8) Ortiz-Urda S, et al:Type VI collagen is required for Ras-driven human epidermal tumorigenesis. Science 307:1727-1728, 2005
 
10) Hasegawa T, et al:Clinical trial of allogeneic cultured demial substitute for the treatment of intractable skin ulcers in 3 patients with recessive dystrophic epidermolysis bullosa. J Am Acad Dermatol 50:803-804, 2004
PubMed
11) Fine JD, et al:Chemoprevention of squamous cell carcinoma in recessive dystrophic epidermolysis bullosa:results of a phase l trial of systemic isotretinoin. J Am Acad Dermatol 50:563-571, 2004
 
12) Ortiz-Urda S, et al:Stable nonviral genetic correction of inherited human skin disease. Nat Med 8:1166-1170, 2002
PubMed
13) Sawaniura D, et al:The majority of keratinocytes incorporate intradermally injected plasmid DNA regardless of size but only a small proportion of cells can express the gene product. JInvest Dermatol 118:967-971, 2002
 
14) Ortiz-Urda S, et al:Injection of genetically engineered fibroblasts corrects regenerated human epidermolysis bullosa skin tissue. J Clin Invest 111:251-255, 2003
 
15) Woodley DT, et al:Intradermal injection of lentiviral vectors corrects regenerated human dystrophic epidermolysis bullosa skin tissue in Vivo. Mol Ther 10:318-326, 2004
PubMed
16) Goto M, et al:Fibroblasts show more potential as target cells than keratinocytes in COL7AI gene therapy of dystrophic epidemolysis bullosa. J Invest Dermatol (in press)
 
17) Hacein-Bey-Abina S, et al:Aserious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 348:255-256, 2003
 
18) Woodley DT, et al:Irllection of recombinant human type W collagen restores collagen function in dystrophic epidermolysis bullosa. Nat Med 10:693-695, 2004
 
P.194 掲載の参考文献
9) 荒木絵里ほか:培養表皮シート移植術を施行した劣性栄養障害型先天性表皮水疱症の2例.皮膚の科学 3:1347-1813, 2004
 
P.198 掲載の参考文献
1) Tomita Y, Suzuki T:Genetics of pigmentary disorders. Am J Med Genet 131C:75-81, 2004
PubMed
2) Spritz RA:Multi-organellar disorders of pigmentation:intracellular traffic jams in mammals, flies and yeast. Trends Genet 15:337-340, 1999
PubMed
3) Tomita Y, et al:Human oculocutaneous albinism caused by single base insertion in the tyrosinase gene. Biochem Biophys Res Cornmun 164:990-996, 1989
PubMed
4) King RA, et al:Non-random distribution of missense mutations within the human tyrosinase gene in type I (tyrosinase-related) oculocutaneous albinism. Mol Biol Med 8:19-29, 1991
 
5) King RA, et al:Temperature-sensitive tyrosinase associated With peripheral pigmentation in oculocutaneous albinism. J Clin Invest 87:1046-1053, 1991
PubMed
6) Gardner JM, et al:The mouse pink-eyed dilution gene:association with human Prader-Willi and Angelman syndromes. Science 257:1121-1124, 1992
PubMed
7) Manga P, et al:Rufous oculocutaneous albinism in southem African Blacks is caused by mutations in the TYRPI gene. Am JHum Genet 61:1095-1101, 1997
 
8) Newton JM, et al:Mutations in the human orthologue of the mouse underwhite gene (uw) underlie a new form of oculocutaneous albinism, OCA4. Am J Hum Genet 69:981-988, 2001
PubMed
9) Inagaki K, et al:Oculocutaneous albmism type 4 is one of the most common t ypes of albinism in Japan. Am J Hum Genet 74:466-471, 2004
 
10) Suzuki T, et al:A Korean case of oculocutaneous albinism type IV caused by a D 157N mutation in the MATP gene. Br J Dermatol 152:174-175, 2005
 
11) Fukamachi S, et al:Mutations in the gene encoding B, a novel transporter protein, reduce melanin content in medaka. Nat Genet 28:381-385, 2001
 
12) Suzuki T, et al:Six novel P gene mutations and oculocutaneous albinism type 2 frequency in Japanese albino patients. J Invest Dermatol 120:781-783, 2003
 
13) Ito S, et al:High Frequency of Hemiansky-Pudlak Syndrome Type 1 (HPS1) Among Japanese Albinism Patients and Functional Analysis of HPSI Mutant Protein. J Invest Demmatol 125:715-720, 2005
 
14) Kawai M, et al:Apatient with subclinical oculocutaneous albinism type 2 diagnosed on getting severely sunburned. Dermatology 210:322-323, 2005
 
15) Suzuki T, et al:High frequency of the Ala481Thr mutation of the P gene in the Japanese population. Am J Med Genet A 118:402-403, 2003
 

第10章 その他の非腫瘍性皮膚疾患

P.202 掲載の参考文献
1) 照井 正ほか:汎発性膿疱性乾癬治療ガイドライン2002. 臨床皮膚科 57:125-130, 2003
 
2) Elder JT, et al:The genetics of psoriasis 2001:the odyssey continues. Arch Dermatol 137:1447-1454, 2001
PubMed
3) 梅澤慶紀ほか:乾癬の痒みとその治療について.臨床皮膚科 59:203-205, 2005
 
4) Mosmrm TR, et al:Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. 1986. J Immunol 136:2348-2357, 1986
 
5) Wrone-Smith T, et al:Dermal injection of immunocytes induces psoriasis. J Clin Invest 98:1878-1887, 1996
PubMed
6) Bata-Csorgo Z, et al:Kinetics and regulation of human keratinocyte stem cell growth in short-term primary ex-vivo culture. Cooperative growth factors from psoriatic lesional T lymphocytes stimulate proliferation among Psoriatic uninvolved, but not normal, stem keratinocytes. J Chn Invest 95:317-327, 1995
PubMed
7) Terui T, et al:Role of neutrophils in induction of acute inflammation in T-cell-mediated immune dermatosis, psoriasis:aneutrophil-associated inflammation-boosting loop. Exp Demlatol 9:1-10, 2000
 
8) Griffin TD, et al:Clinical and histological heterogeneity of psoriatic plaques. Therapeutic relevance. Arch Dermatol 124:216-220, 1988
PubMed
9) Terui T, et al:HLA-DR antigen expression on keratinocytes in highly inflamed parts of psoriatic lesions. Br J Dermatol 116:87-93, 1987
PubMed
10) Krueger JG:The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 46:1-23, 2002
PubMed
P.207 掲載の参考文献
1) Behcet HZ:Uber rezidivierende, aphthose, durch ein Virus verursachte Geschwure am Mund, am Auge und an den Genitalien. Dermatol Wochenschr 105:1152-1157, 1937
 
2) Sakane T, et al:Behcet's disease. New Eng J Med 341:1284-1291, 1999
PubMed
3) 金子史男:Behcet病,玉置邦彦他 編:最新皮膚科学大系第4巻 紅斑.滲出性紅斑 紫斑 脈管系の疾患.中山書店,東京, p40-51, 2003
 
4) Kaneko F, et al:Immunological studies on aphthous ulcer and erythema nodosum-like eruptions in Behcet's disease. Br J Dermatol 113:303-312, 1985
PubMed
5) Jorizzo n, et al:Behcet's syndrome. lmmunopathologic and histopathologic assessment of pathergy lesions is useful in diagnosis and follow up. Arch Pathol Lab Med 109:747-751, 1985
 
6) Ohno S, et al:Close association of HLA-Bw51 with Behcet's disease. Arch Ophthalmol 100:1455-1458, 1982
PubMed
7) Zouboulis CC, et al:Adamantiades-Behcet's disease:Epidemiology in Germany and in Europe, Sungnack L, et al eds:Behcet's Disease:A guide to its Clinical Understanding. Springer, Berlin, p 157-169, 2001
 
8) Mizushima Y, et al:Induction of Behcet's disease symptoms after dental treatment and streptococcal antigen skin test. J Rheumatol l 5:1029-1030, 1988
 
9) Kaneko F, et al:Streptococcal infection in the pathogenesis of Behcet's disease and clinical effects of minocycline on the disease symptoms. Yonsei Med J 38:444-454, 1997
PubMed
10) Isogai E, et al:Role of Streptococcus sanguis and traumatic factors in Behcet's disease. J Appl Res 3:64-75, 2003
 
11) Yamashita N, et al:Role of gammadeltaT lymphocyteskmthe development of Behcet's disease. Clin Exp Immunol 107:241-247, 1997
 
12) Yasuoka H, et al:Autoreactive CD8+cytotoxic T lymphocytes to major histocompatibility complex class I chain-related gene A in patients with Behcet's disease. Arthritis Rheum 50:3658-3662, 2004
 
13) Tojo M, et al:Bes-1 DNA fragment encording streptococcal antigen in skn lesions from patients with Behcet's disease. J Appl Res 3:232-238, 2003
 
14) Tojo M, et al:Detection of herpes virus genomes in skin lesions from patients with Behcet's disease and other related inflammatory diseases. Acta Dermatol Venereol 83:124-127, 2003
 
15) Stanford M, et al:Oral tolerization with peptide 336-351 1inked to cholera toxin B subunit in preventing relapses of uveitis in Behcet's disease. Clin Exp Immunol 137:201-208, 2004
 
P.212 掲載の参考文献
1) 池澤善郎:DIHSやSJS/TENのような重症薬疹の治療と問題点.医学のあゆみ 205:965-971, 2003
Medical*Online
2) Roajeau JC:The spectrum of Stevens-Jokmson syndrome and toxic epidermal necrolysis:a clinical classification. J Invest Dermatol 102:28s-30s, 1994
 
3) Roueau JC:Stevens-Johnson syndrome and toxic epidermal necrolysis are severity varients of the same disease, different from erythema multiforme, 日皮会誌107:211-214, 1997
 
4) 橋本公二:DIHSの病態と治療.第54回日本アレルギー学会 (パシフィコ横浜) ,教育セミナー5,2004
 
5) 池澤善郎 (責任編集):特集DIHS (薬剤誘発性過敏症症候群).Visual Dermatology 10:2005
 
6) Roujeau JC, et al:Acute generalized exanthematous pustulosis. Analysis of 63 cases, Arch Dermatol 127:1333-1338, 1991
PubMed
7) Aihara M, et al:sensitivity syndrome associated with cytomegalovirus infection. Br J Dermatol (in press)
 
8) 桝沢正広ほか:IgA欠損を伴ったhypersensitivity syndrome の1例.アレルギー 50:312, 2001
 
9) 池澤善郎:IV型アレルギー反応の機序,福田 健編:総合アレルギー学.南山堂,東京,p148-167, 2004
 
10) 池澤善郎:薬物アレルギー,福田 健編:総合アレルギー学. 南山堂,東京,p547-564, 2004
 
11) 近藤直美ほか:最近経験した伝染性単核症について- Epstein-Barrウイルスに関する抗体測定の意義.小児科診療 46:123-126, 1983
 
12) 池澤善郎ほか:サイトメガロウイルスとhypersensitivity syndrome.アレルギーの臨床 21:370-373, 2001
 
13) Kazuko Nakamura, et al:Clinical feature of drug-induced hypersensitivity syndrome in Japan. The 1st Drug Hypersensitivity Meeting (Bem), 5-8, 2004
 
14) Ikezawa Z, et al:ARole of Herpes Virus Infection in Drug Eruptions, Luncheon Seminar"What:s New in Drug Allergy" in The lst Drug Hypersensitivity Meeting, (Bem), 2004.
 
15) Guibal F, et al:Characteristics of toxic epidermal necrolysis in patients undergoing long-term glucocorticoid therapy. Arch Dermatol 131:669-672, 1995
PubMed
P.216 掲載の参考文献
1) Uno H, et al:Studies of common baldness of the stump-tailed macaque:1. Distribution of hair fbllicles. J Invest Dermatol 49:288-296, 1967
 
2) Takashima I, et al:Alopecia androgenetica:its incidence in Japanese and associated conditions, in Orfanos CS, et al eds:Hair Research:Status and Future Aspedts. Springer, Berlin, p287-293, 1981
 
3) 板見 智:日本人成人男性における毛髪 (男性型脱毛) に関する意識調査.日本医事新報 4209:27-29, 2004
Medical*Online
4) Imperato-McGinley J, et al:The androgen control of sebum production. Studies of subjects with dihydrotestosterone deficiency and complete androgen insensitivity. J Clin Endocrilol Metab 76:524-528, 1993
 
5) Choudhry R, et al:Localization of androgen receptors in human skin by immunohistochemistry:implications for the hormonal regulation of hair growth, sebaceous glands and sweat glands. J Endocrinol 133:467-475, 1992
PubMed
6) Itami S, et al:Interaction between dermal papilla cells and follicular epithelial cells in vitro:effect of androgen. Br J Dermatol 132:527-532, 1995
PubMed
7) Nakanishi S, et al:Expression of androgen receptor, type and type 5 a-reductase in huiman dermal papilla cells, in Randall VA, et al eds:Hair Research for the Next Millennium. Elsevier, Netherlands, p333-337, 1996
 
8) Itami S, et al:Characterization of 5a-reductase in cultured human dermal papilla cells from beard and occipital scalp hair. J Invest Denmatol 96:57-60, 1991
 
9) Itami S, et al:Androgen induction of folhcular epithelial cell growth is mediated via insulin-like growth factor-I from dermal papilla cells. Biochem Biophys Res Commun 212:988-994, 1995
PubMed
10) Inui S, et al:Androgen-inducible TGF-β1from balding dermal papilla cells inhibits epithelial cell growth:aclue to understand paradoxical effects of androgen on human hair growth. FASEB J 16:1967-1969, 2002
 
11) Foitzik K, et al:Control of murine hair follicle regression (catagen) by TGF-β1 in vivo. FASEB J 14:752-760, 2000
 
12) Michelet JF, et al:Activation of cytoprotective prostaglandin synthase-1 by minoxidil as a possible explanation for its hair growth-stimulating effect. J Invest Dermatol 108:205-209, 1997
PubMed
13) Li M, et al:Minoxidil-induced hair growth is mediated by adenosine in cultured dermal papilla cells:possible involvement of sulfonylurea receptor 2B as a target of minoxidil. J Invest Dermatol 117:1594-1600, 2001
PubMed
14) The Finasteride Male Pattern Hair Loss Study Group:Long-term (5-year) multinational experience with finasteride l mg in the treatment of men with androgenetic alopecia Eur J Dermatol 12:38-49, 2002
 
15) Kawashima M, et al:Finasteride in the treatment of Japanese men with male pattern hair loss. Eur J Dermatol 14:247254, 2004
 

第11章 光線と皮膚

P.220 掲載の参考文献
1) 川田 暁:光老化.日皮会誌 110:1878-1879, 2000
 
2) 川田 暁:光老化皮膚のメカニズムとその予防.日皮会誌 114:1875-1880, 2004
 
3) 川田 暁:光老化皮膚の諸症状の診断と鑑別診断,川田 暁 編:光老化皮膚.南山堂,東京,p2-12, 2005
 
4) 花田勝美:光老化-ほんとうにしわ,しみは不要か-.日皮会誌 114:1257-1263, 2004
 
5) Bemstein EF, et al:Ultraviolet radiation activates the human elastin promoter in transgenic mice:a novel in vivo and in vitro model of cutaneous photoaging. J Invest Dermatol 105:269-273, 1995
 
6) Fisher GJ, et al:Pathophysiology of premature skin aging induced by ultraviolet light. N Engl J Med 337:1419-1428, 1997
PubMed
7) 遠藤英樹ほか:Qスイッチルビーレーザー,川田 暁 編:光老化皮膚.南山堂,東京,p22-34, 2005
 
8) 川田 暁:レーザー療法,山口 徹,北原光夫総編:今日の治療指針2006年版.医学書院,東京 (in press)
 
9) Kawada A, et al:Clinical improvement of solar lentigines and ephelides with an intense pulsed light source. Dermatol Surg 28:504-508, 2002
PubMed
10) Kawada A, et al:Videomicroscopic and histopathological investigation of intense pulsed light therapy for solar lentigines. J Dermatol Sci 29:91-96, 2002
PubMed
11) 川田 暁ほか:IPL (Intense Pulsed Light) による毛穴治療とビデオマイクロスコープによる評価.Fragrance J 33:48-51, 2005
Medical*Online
12) 川田 暁:サンスクリーン.皮膚臨床 44:1249-1255, 2002
 
13) 川田 暁ほか:光防御とサンスクリーン剤.佐藤吉昭監修, 市橋正光,堀尾 武編:光線過敏症 改訂3版.金原出版, 東京,P263-282, 2002
 
14) 川田 暁:紫外線と皮膚,宮地良樹,長沼雅子編:化粧品. 外用薬研究者のための皮膚科学.文光堂,東京,p45-48, 2005
 
15) 川田 暁:「光老化 (しみ) 外来」における診察.皮膚病診療 23:835-839, 2001
 
P.224 掲載の参考文献
1) 戸倉新樹:光線過敏型薬疹,最新皮膚科学体系第5巻.中山書店,東京,75-82, 2004
 
2) 戸倉新樹:光アレルギーの基礎と臨床.口皮会誌 111:1-12, 2001
 
3) Tokura Y, et al:Photohaptenic properties of fluoro-quinolones. Photochem Photobiol 64:838-844, 1996
 
4) Ohshima A, et al:Formation of antigenic quinolone photoadducts on Langerhans cells initiates photoallergy to systemically administered quinolone in mice. J Invest Dermatol 114:569-575, 2000
PubMed
5) Tokura Y, et al:Cross-reactivity in murine fluoroquinolone photoallergy:exclusive usage of TCR VB13 by immune T cells that recognize fluoroquinolone-photomodified cells. J Immunol 160:3719-3728, 1998
 
6) Tokura Y, et al:Quinolone-photoconjugated major histocompatibility complex class H-binding peptides with lysine are antigenic for T cells mediating murine quinolone photoalergy. J Invest Dermatol 117:1206-1211, 2001
 
7) Sugita K, et al:Chronic actinic dermatitis associated with adult T-cell leukemia. J Am Acad Dermatol 52:S38-40, 2005
 
P.227 掲載の参考文献
1) http://www.who.int/mediacentre/news/notes/2005/np07/en/index.html
PubMed
2) Karagas MR, et al:Use of taming devices and risk of basal cell and squamous cell skin cancers. J Natl Cancer Inst 94:224-226, 2002
 
3) Ichihashi M, et al:UV-induced skin damage. Toxicology 189:21-39, 2003
PubMed
4) Pfeifer GP, et al:Mutations induced by ultraviolet light. Mutat Res 571:19-31, 2005
 
5) Jans J, et al:Powerful skin cancer protection by a CPD-photolyase transgene. Curr Biol 15:105-115, 2005
PubMed
6) Nishigori C, et al:Role of reactive oxygen species in skin carcinogenesis. Antioxid Redox Signal 6:561-570, 2004
PubMed
7) Kunisada M, et al:8-Oxoguanine formation induced by chronic UVB exposure makes Ogg1 knockout mice susceptible to skin carcinogenesis. Cancer Res 65:6006-6010, 2005
PubMed
8) Ullrich SE:Mechanisms underlying UV-induced immune suppression. Mutat Res 571:185-205, 2005
PubMed
9) Bowden GT:Prevention of non-melanoma skin cancer by targeting ultraviolet-B-hght signalling. Nat Rev Cancer 4:23-35, 2004
 
10) Daya-Grosjean L, et al:Sonic hedgehog signaling inbasal cell carcinomas. Cancer Lett 225:181-192, 2005
 
11) Giglia-Mari G, et al:TP53 mutations in human skin cancers. Hum Mutat 21:217-228, 2003
PubMed
12) Lazarov M, et al:CDK4 coexpression with Ras generates malignant human epidermal tumorigenesis. Nat Med 8:1105-1114, 2002
PubMed
13) Dajee M, et al:NF-κBblockade and oncogenic Ras trigger invasive human epidermal neoplasia. Nature 421:639-643, 2003
 
14) Takata M, et al:Constitutive activation of the mitogen-activated protein kinase signaling pathway in acral melanomas. J Invest Demiatol 125:318-322, 2005
PubMed
15) Yamazaki F, et al:Development of a new mouse model (xeroderma pigmentosum A-deficient, stem cell factor-transgenic) of ultraviolet B-induced melanoma. J Invest Dermatol 125:521-525, 2005
PubMed
P.231 掲載の参考文献
1) Cleaver JE:Defective repair replication of DNA in xeroderma pigmentosum. Nature 218:652-656, 1968
PubMed
2) Wood, RD:DNA repair in eukalyotes. Annu Rev Biochem 65:135-167, 1996
PubMed
3) Masutani C, et al:The XPV (xeroderma pigmentosum variant) gene encodes human DNA polymerase 7. Nature 399:700-704, 1999
 
4) 錦織千佳子:DNA障害による皮膚障害,玉置邦彦ほか編:最新皮膚科学大系第16巻.中山書店,東京, p301-313, 2003
 
5) Miyauchi-Hashimoto H, et al:Enhanced inflammation and immunosuppression by ultraviolet radiation in xeroderma pigmentosum group A (XPA) model mice. J Invest Dermatol 107:343-348, 1996
 
6) Nishigori C, et al:Evidence that DNA damage triggers interleukin-10 cytokine production in UV-irradiated murine keratinocytes. Proc Natl Acad Sci USA 93:10354-10359, 1996
PubMed
7) Nishigori C, et al:High prevalence of the point mutation in exon 60f the xeroderma pigmentosum group A-complementing (XPAC) gene in xeroderma pigmentosum group A patients in Tunisia. Am J Human Genet 53:1001-1006, 1993
 
8) Hanawalt PC:Transcription-coupled repair and human disease. Science 266:1957-1958, 1994
PubMed
9) Nishigori C, et al:Acase of xeroderma pigmentosum group F with late onset of clinical symptoms. Arch Dermatol 122:510-511, 1986
 
10) Moriwaki S-1, et al:Acase of xeroderma pigmentosum complementation group F with neurological abnormalities. Br J Dermatol 128:91-94, 1993
 
11) Matsumura Y, et al:Characterization of molecular defects in xeroderma pigmentosum group F in relation to its clinically mild symptoms. Human Mol Genetics 7:969-974, 1998
 
12) 正木太朗ほか:DNAポリメラーゼH遺伝子に変異をみとめた色素性乾皮膚症バリアント群の小児例.第27回日本光生物光医学抄録集:53, 2005
 
13) 森脇真-ほか:色素乾皮症の診断-最近の進歩.臨皮 53:79-83, 1999
 
14) Nishigori C, et al:Gene alterations and clinical characteristics of xeroderrna pigmentosum group A patients in Japan. Arch Dermatol 130:191-197, 1994
 
15) Itoh T, et al:The photocarcinogenesis of antibiotic lomefioxacin and UVA radiation is enhanced in xeroderma pigmentosum group A gene-deficient mice. J Invest Dermatol 125:554-559, 2005
 
16) Douki T, et al:Bipyrimidine photoproducts rather than oxidative lesions are the main type of DNA damage involved in the genotoxic effect of solar UVA radiation. Biochemistry 42:9221-9226, 2003
PubMed
17) Besaratinia A, et al:G-to-T transversions and small tandem base deletions are the hallmark of mutations induced by ultraviolet a radiation in mammalian cells. Biochemistry 43:8169-8177, 2004
 
18) Yarosh D, et al:Effect of topically applied T4 Endonuclease V in liposomes on skin cancer in xeroderma pigmentosum:a randomised study. Lancet 357:926-929, 2001
PubMed

第12章 悪性黒色腫

P.235 掲載の参考文献
1) Davies H, et al:Mutations of the BRAF gene in human cancer. Nature 417:949-954, 2002
PubMed
2) Wu H, et al:PTEN signaling pathways in melanoma. Oncogene 22:3113-3122, 2003
PubMed
3) Stahl JM, et al:Deregulated Akt3 activity promotes development of malignant melanoma Cancer Res 64:7002-7010, 2004
PubMed
4) Bemett DC:Human melanocyte senescence and melanoma susceptibility genes. Oncogene 22:3063-3069, 2003
 
5) Takata M, et al:Constitutive activation of the MAPK signaling pathway in acral melanomas. J Invest Dermatol 125:318-322, 2005
PubMed
6) Clark WH Jr, et al:The biologic forms of malignant melanoma. Hum Pathol 17:443-450, 1986
PubMed
7) Ackerman AB, et al:Aunifying concept of malignant melanoma:biologic aspects. Hum Pathol 17:438-440, 1986
PubMed
8) Bastian BC, et al:Gene amplifications characterize acral melanoma and permit the detection of occult tumor cells in the surrounding skin. Cancer Res 60:1968-1973, 2000
PubMed
9) Bastian BC, et al:Classifying melanocytic tumors based on DNA copy number changes. Am J Pathol 163:1765-1770, 2003
PubMed
10) Maldonado JL, et al:Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst 95:1878-1890, 2003
PubMed
11) Saida T:Malignant melanoma on the sole:how to detect the early lesions efficiently. Pigment Cell Res 13:135-139, 2000
PubMed
12) Saida T, et al:Significance of dermoscopic pattems in detecting malignant melanoma on acral volar skin:results of a multicenter study in Japan. Arch Dermatol 140:1233-1238, 2004
 
13) Yamaura M, et al:Specific dermoscopy patterns and amplifications of cyclin Dl gene define histologically unrecognizable early lesions of acral melanoma in situ. Arch Dermatol 141:1413-1418, 2005
 
14) Takata M, et al:Two cases of unusual acral melanocytic tumors:illustration of molecular cytogenetics as a diagnostic tool. Hum Pathol 34:89-92, 2003
PubMed
15) Takata M, et al:Genome profiling of melanocytic tumors using multiplex ligation-dependent probe amplification (MI. PA):Its usefulness as an adjunctive diagnostic tool for melanocytic. J Dermatol Sci 40:51-57, 2005
 
P.238 掲載の参考文献
1) Brochez L, et al:Serological markers for melanoma. Brit J Dermatol 143:256-268, 2000
 
2) Rorsman H, et al:Determination of 5-S-cysteinyldopa in melanomas with a fluorimetric method. Yale J Biol Med 46:516-522, 1973
PubMed
3) Wakamatsu K, et al:Evaluation of 5-S-cysteinyldopa as a marker of melanoma progression:10 years:experience. Melanoma Res 12:245-253, 2002
PubMed
4) Bosserhoff AK, et al:Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res 57:3149-3153, 1997
PubMed
5) 八田尚人ほか:黒色腫の血清腫瘍マーカーとしての melanoma inhibitory activity (MIA) の有用性.日皮会誌 113:145-149, 2003
 
6) Fragnart OC, et al:Particle counting immunoassay of S 100 protein in serum. Possible relevance in tumors and ischemic disorders of the central nervous system. Clini Chem 34:1387-1391, 1988
 
7) Bottoni U, et al:S100 serum level:atumour marker for metastatic melanoma. Melanoma Res 13:427-429, 2003
 
8) Jury CS, et al:Rising levels of serum S100 protein precede other evidence of disease progression in patients with malignant melanoma. Br J Denmatol 143:269-274, 2000
PubMed
9) Banfalvi T, et al:Comparison of prognostic significance of serum 5-S-Cysteinyldopa, LDH, and S 100B protein in stage m-Wmalignant melanoma. Pathology Oncology Research 8:183-187, 2002
 
10) Deichmann M, et al:S100-beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer Stage IV Melarloina. J Clin Oncol 17:1891-1896, 1999
PubMed
11) Nakatsura T, et al:Identification of glypican-3 as a novel tumor marker for melanoma. Clin Cancer Res 10:6612-6621, 2004
PubMed
12) Ikuta Y, et al:Highly sensitive diagnosis of melanoma at an early stage by detecting the serum SPARC and glypican-3 1evels. Clin Cancer Res 11:8079-8088, 2005
 

第13章 皮膚のリンフォーマ

P.242 掲載の参考文献
1) Jaffe ES, et al:Mature T-cell and NK-cell neoplasms:Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon, p189-235, 2001
 
2) Hoque SR, et al:Subcutaneous panniculitis-like T-cell lymphoma:aclinicopathological, immunophenotypic and molecular analysis of six patients. Br J Dermatol 148:516-525, 2003
 
3) Kunisada M, et al:Nasal-type natural killer cell lymphoma preceded by benign panniculitis arising in an asymptomatic HTLV-1 carner. Int J Dermatol 42:710-714, 2003
 
4) Kase S, et al:Epstein-Barr Virus-infected malignartt T/NK-cell lymphoma in a patient with hypersensitivity to mosquito bites. Int J Surg Pathol 12:265-272, 2004
 
5) Cho KH, et al:Epstein-Barr Virus-associated peripheral T-cell lymphoma in adults with hydroa vacciniforme-like lesions. Clin EXp Dermatol 26:242-247, 2001
PubMed
6) Shirasaki F, et al:Epstein-Barr virus-associated T-cell lymphoma:acase of eyelid swelling and intramuscular infiltration mimicking dermatomyositis. Br J Dermatol 147:1244-1248, 2002
 
7) Okano M, et al:Proposed guidelines for diagnosing chronic active Epstein-Banvirus infection. Am J Dermatol 80:64-69, 2005
 
8) Kimura H, et al:Prognostic factors for chronic active Epstein-Barr Virus infection. J Infect Dis 187:527-533, 2003
PubMed
9) 吉田正巳:最新皮膚科学大系15ウイルス性疾患性感染症. 中山書店,東京,p42-46, 2003
 
10) 山本剛伸ほか:皮膚科外来でできるEBウイルス検査法.臨床皮膚科 57:87-93, 2003
 
P.245 掲載の参考文献
1) Jaffe ES, et al:Pathology and genetics of tumours of haematopoietic and lymphoid tissues;in World Health Organization Classification of tumours, (Kleihues P, Sobin LH ed), IARC Press, Lyon, 109-230, 2001
 
2) Willemze R, et al:EORTC classification for primary cutaneous lymphomas:aproposal from the Cutaneous Lym-phoma Study Group of the European Organization for Research and Treatment of Cancer. Blood 90:354-371, 1997
 
3) Willemze R, et al:EORTC classification for primary cutaneous lymphomas:a comparison with the R. E. A. L. Classification and the proposed WHO CIassification. Ann Oncol 11 (Suppl 1):11-15, 2000
 
4) Jaffe ES, et al:Cutaneous lymphomas:aproposal for a unified approach to classification using the R. E. A. L. /WHO CIassification. Ann Oncol 11 (Suppl 1):17-21, 2000
 
5) 菊池昌弘:新WHO分類の意義:分類の概観,思想,特徴, 問題点.病理と臨床 21:130-133, 2003
Medical*Online
6) Willemze R, et al:WHO-EORTC classification for cutaneous lymphomas. Blood 105:3768-3785, 2005
PubMed
P.249 掲載の参考文献
1) Yagi H, et al:Cutaneous type of adult T cell leukemia/lymphoma:a new entity among cutaneous lymphomas. J Derma-tol 30:641-643, 2003
 
2) 八木宏明:EBMからみた菌状息肉症とセザリー症候群の標準的治療.Skin Cancer 19:48-54, 2004
 
3) 日本皮膚悪性腫瘍学会編:皮膚悪性腫瘍取扱い規約第1版. 金原出版,東京,p113, 2002
 
4) Kaye FJ, et al:Arandomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 321:1784-1790, 1989
 
P.254 掲載の参考文献
1) Jaffe ES et al eds:WHO Classification of Pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC press, Lyon, 2001
 
2) Willemze R, et al:EORTC classification for primary cutaneous lymphomas:aproposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood 90:354-371, 1997
 
3) Willemze R, et al:WHO-EORTC classification for cutaneous lymphomas. Blood 105:3768-3785, 2005
PubMed
4) Harris NL, et al:Arevised European-American classification of lymphoid neoplasms:aproposal from the International Lymphoma Study Group. Blood 84:1361-1392, 1994
 
5) The world health organization classification of malignant lymphomas in japan:incidence of recently recognized entities. Lymphoma study group of Japanese pathologists:Pathol Int 50:696, 2000
 
6) 山口素子:NKリンパ腫の治療.臨床血液 45:209, 2004
 
7) 日本皮膚悪性腫瘍学会編:悪性リンパ腫総論,皮膚悪性腫瘍取扱い規約.金原出版,東京,2002
 
8) 伊藤 薫ほか:造血系,王置邦彦ほか編:最新皮膚科学大系 13 神経系腫瘍間葉系腫瘍.中山書店,東京,2002
 
9) 辻野志穂:悪性リンパ腫の分子生物学的病態解析,日本臨床 58:612-617, 2000
Medical*Online
10) 三谷祥子ほか:白血病.リンパ腫悪性リンパ腫の遺伝子診断.医学のあゆみ 197:1205-1210, 2001
 
11) 伊藤 薫:リンパ腫の遺伝子検査法.MB Derma 71:93-98, 2003
 
P.258 掲載の参考文献
1) Jaffe ES, et al:Tumors of haemopoietic and lymphoid tissue. WHO classification of tumor IARC press, Lyon, 2001
 
2) Willemze R, et al:WHO-EORTC classification for cutaneous lymphomas. Blood 105:3768-3785, 2005
PubMed
3) Burg G, et al:Cutaneous lymphomas. Taylor & Francis, Boca Raton London New York Singapore, 2005
 
4) Bonnekoh B, et al:Complete remission of a primary cutaneous B-cell lymphoma of the lower leg by first-line monotherapy with the CD20-antibody rituximab. J Cancer Res Clin Oncol 128:161-166, 2002
PubMed
5) Halaas JL, et al:R-CHOP-14 in patients with diffuse large B-cell lymphoma:feasibility and preliminary efficacy. Leuk Lymphoma 46:541-547, 2005
PubMed
6) Czuczman MS, et al:Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin:s lymphoma treated with rituximab plus CHOP chemotherapy:9-year follow-up. J Clin Oncol 22:4711-4716, 2004
PubMed
7) Slater DN:The new World Health Organization classification of haematopoietic and lymphoid tumours:adermatopatho-logical perspective. Br J Dermatol 147:633-639, 2002
 
8) Cerroni L, et al:Primary cutaneous follicle center cell lymphoma. Leuk Lymphoma 42:891-900, 2001
PubMed
9) Servitje O, et al:Primary cutaneous marginal zone B-cell lymphoma:aclinical, histopathological, immunophenotypic and molecular genetic study of 22 cases. Br J Demlatol 147:1147-1158, 2002
 
10) Hembury TA, et al:Primary cutaneous diffuse large B-cell lymphoma:aclinicopathologic study of 15 cases. Am J Clin Pathol 117:574-580, 2002
 

第14章 ダーモスコピー

P.262 掲載の参考文献
1) 斎田俊明,大原國章ほか編:カラーアトラスDermoscopy, 金原出版,東京,2003
 
2) 斎田俊明:色素細胞母斑の統一概念.Visual Dermatol 2:1128-1136, 2003
 
3) Saida T:Malignant melanoma on the sole:how to detect the early lesions efficiently. Pigment Cell Res 13:135-139, 2000
PubMed
4) Saida T:The concept of de novo origin of cutaneous malignant melanoma. Eur J Dermatol 4:252-254, 1994
 
5) Saida T:Lessons learned from studies of the development of early melanoma. Int J Clin Oncol 10:371-374, 2005
PubMed
6) Saida T, et al:In vivo observation of magnified features of pigmented lesions on volar skin using Video macroscope:usefulness of epiluminescence techniques in clinical diagnosis. Arch Dermatol 131:298-304, 1995
PubMed
7) Oguchi S, et al:Characteristic epiluminescent microscopic features of early malignant melanoma on glabrous skin:a Videomicroscopic analysis. Arch Dermatol 134:563-568, 1998
PubMed
8) Saida T, et al:Dermoscopy for acral pigmented lesions. Clin Dermatol 20:279-285, 2002
PubMed
9) Saida T, Miyazaki A, et al:Acrolentiginous melanoma. Marghoob AA, et al ed:Atlas of Dermoscopy. Taylor & Francis, London, P221-233, 2005
 
10) Grin CM, Saida T:Pigmented nevi of the palms and soles. Marghoob AA, et al ed:Atlas of Dermoscopy. Taylor & Francis, London, p271-279, 2005
 
11) Saida T, et al:Significance of dermoscopic patterns in detecting mahgnant melanoma on acral volar skin:results of amulticenter study in Japan. Arch Dermatol 140:1233-1238, 2004
 
12) Miyazaki A, et al:Anatomical and histopathological correlates of the dermoscopic patterns seen in melanocytic nevi on the sole:aretrospective study. J Am Acad Dermatol 53:230-236, 2005
 
13) Kawabata Y, Tamaki K:Distinctive dematoscopic features of acral lentiginous melanoma in situ from plantar melanocytic nevi and their histopathologic correlation. J Cutan Med Surg 2:199-204, 1998
PubMed
14) Saida T, et al:Clinical guidelines for the early detection of plantar malignant melanoma. J Am Acad Dermatol 23:3740, 1990
 
15) Ishihara Y, et al:Early acral melanoma in situ diagnosed with adermoscopic feature of the parallel ridge pattern. Am J Dermatopathol 28:2006 (in press)
 
16) Yamaura M, et al:Specific dermoscopy patterns and amplification of cyclin DI gene define histopathologically unrecognizable early lesions of acral melanoma in situ. Arch Dermatol 141:1413-1418, 2005
PubMed
17) 斎田俊明:掌蹠の色素性病変のダーモスコピーによる診断と鑑別.日皮会誌 115:2005(印刷中)
 
P.266 掲載の参考文献
1) Soyer HP, et al:Dermoscopy of Pigmented Skin Lesions. An Atlas Based on the Consensus Net Meeting on Dermoscopy. Edra, Milano, pp 1-273, 2001
 
2) Ackerman AB, et al:Naming acquired melanocytic nevi. Unna:s, Miescher:s, Spitz:s, Clark:s. Am J Dermatopathol 12:193-209, 1990
 
3) Argenziano G, et al:Dermoscopy of pigmented skin lesions:Results of a consensus meeting Via the Internet. J Am Acad Dermatol 48:679-693, 2003
PubMed
4) Braun R, et al:Pattern analysis:A two-step procedure for the dermoscopic diagnosis of melanoma. Clin Dermatol 20:236-239, 2002
PubMed
5) Stolz W, et al:ABCD rule of dermatoscopy:A new practical method for early recognition of malignant melanoma. Eur J Dermatol 4:521-527, 1994
 
6) Stolz W, et al:Color Atlas of Dermatoscopy. 2nd Ed. Blackwell, Berlin, 2002
 
7) 斎田俊明:良性メラノサイト系病変と悪性黒色腫の鑑別 (2nd step) ,斎田俊明ほか編:カラーアトラスDermoscopy. 金原出版,東京,p89-101, 2005
 
8) Menzies SW, et al:Frequency and morphologic characteristics of invasive melanomas lacking specific surface microscopic features. Arch Dermatol 132:1178-1182, 1996
PubMed
9) Menzies SW, et al:An Atlas of Surface Microscopy of Pigmented Skin Lesions:Dermoscopy. 2nd Ed. McGraw-Hill, Sydney, 2003
 
10) Argenziano G, et al:Epiluminescence microscopy for the diagnosis of doubtful melanocytic skin lesions. Comparison of the ABCD rule of dermatoscopy and a new 7-point checklist based on pattern aiialysis. Arch Dermatol 134:1563-1570, 1998
 
11) Soyer HP, et al:Three-point checklist of dermoscopy. A new screening method for early detection of melanoma. Dermatology 208:27-31, 2004
PubMed
P.270 掲載の参考文献
1) Soyer HP, et al:Demoscopy of Pigmented Skin Lesions. Edra Medical Publishing and New Media, Milan, p21, 2001
 

技術資料編

P.279 掲載の参考文献
1) Kato M, et al:Phrmacokinetic and pharmacodynamic evaluation of central effect of the novel antiallergic agent betotastine besilate, Arzneimittel-Forschung 47:1116-1124, 1997
 
2) 鵜飼幸太郎ほか:新規坑アレルギー剤ベシル酸ベトタスチン (TAU-284) の臨床薬理試験-鼻汁中好酸球および鼻腔開存度に対する影響-.臨床薬理 13:1401-1412, 1997
 
3) 神沼修ほか:Biologocal & Pharmaceutical. Bul-letin 21:441, 1998
 
4) Yokota H, et al:Phase I study of TAU-284 single oral administration in healthy male volunteers. J Clin Therapeut Med 13:1137-1153, 1997
 
5) Nakahara T, et al:Bepotasutine besilate rapidly inhibits miteantigen induced immediate reactions in atopic dermatitis. J Dermatol Sci 25:59-63, 2001
 
6) 古江増隆:ベシル酸ベポタスチンの即効性について,中原剛史ほか編:臨床と研究.大道学館,福岡,p157-160, 2004
 
7) Frue M, et al:Effects of cetirizine and epinastine on the skin response to histamine iontophoresis. J Dermatol Sci 25:59-63, 2001
 
8) Morita K, et al:Rapid effects of olopatadine hydrochloride on the histamine-induced skin responses. J Dermatol 29:709-712, 2002
PubMed
9) 秀 道広:全国523名の蕁麻疹患者の意識調査結果報告.Allergology & Immunology 12:132. 139, 2005
 
10) 秀 道広:蕁麻疹.アレルギー.免疫 12:101-106, 2005
 
P.283 掲載の参考文献
1) 日本医真菌学会疫学調査委員会:1991年次皮膚真菌症疫学調査成績.真菌誌 34:493-502, 1993
 
2) 日本医真菌学会疫学調査委員会:1992年次皮膚真菌症疫学調査成績.真菌誌 36:87-95, 1995
 
3) 日本医真菌学会疫学調査委員会:1996年次皮膚真菌症疫学調査成績.真菌誌 41:187-196, 2000
 
4) 日本医真菌学会疫学調査委員会:1997年次皮膚真菌症疫学調査成績.真菌誌 42:11-18, 2001
 
5) Japan Foot Week研究会:本邦における足.爪白癬の疫学調査成績.日皮会誌 111:2101-2112, 2001
 
6) Niwarto Y, et al:In Vitro and in Vivo antidermato-phyte activities of NND-502, a novel optically active imidazole antimycotic agent. Antimicrob Agents Chemother 42:967-970, 1998
 
7) Uchida K, et al:In vitro antifungal activity of luli-conazole (NND-502), a novel imidazole antifungal agent. J Infect Chemother 10:216-219, 2004
 
8) Uchida K, et al:In vitro activity of novel imidazole antifungal agent NND-502 against Malassezia species, Int J Antimicrob Agents 21:234-238, 2003
PubMed
9) Niwano Y, et al:Inhibition of sterol 14 alpha-demethylation of Candida albicans with NND-502, anovel optically active imidazole antimycotic agent. Med Mycol 37:351-355, 1999
 
10) Uchida K, et al:Achievement of complete mycological cure by topical antifungal agent NND-502 in guinea pig model of tinea pedis. Microbiol Immunol 47:143-146, 2003
PubMed
11) Watanabe S, et al:submitted for publication.
 
12) 社内資料
 
P.288 掲載の参考文献
1) Winter GD:Formation of the scab and the rate of epithelialization of superficial wounds in the skin of the young domestic pig. Nature 193:293-294, 1962
 
2) Hinman CD, et al:Effect of air exposure and occlusion on experimental human skin wounds. Nature 200:377-378, 1963
PubMed
3) Eaglestein WH:Experiences with biosynthetic dressings. J Am Acad Dermatol 12:434-440, 1985
 
4) Hutchinson JJ:Prevalence of wound infection under occlusive dressings:Acollective survey of reported research. Wounds 1:123-133, 1989
 
5) Friedman SJ, et al:Management of leg ulcers with hydrocolloid occlusive dressing. Arch Dermatol 120:1329-1336, 1984
PubMed
P.292 掲載の参考文献
1) Elmore AR:Final report of the safety assessment of L-Ascorbic Acid, Calcium Ascorbate, Magnesium Ascorbate, Magnesium Ascorbyl Phosphate, Sodium Ascorbate, and Sodium Ascorbyl Phosphate as used in cosmetics. Int J Toxicol 24 (Suppl 2):51-111, 2005
 
2) Takashima H, et al:Ascorbic acid esters and skin pigmentation. Ame Perfumer and cosmetics 86:29-36, 1971
 
3) 鈴木晴恵:イオントフォレーシスを用いた色素沈着症の治療.日美外報 20:8-29, 1998
 
4) Kameyama k, et al:Inhibitory effect of magnesium Lascorbyl-2-phosphate (VC-PMG) on melanogenesis in vitro and in vivo. J Am Acad Deumatol 34:29-33, 1996
 
5) Kobayashi S, et al:Protective effect of magnesium-L-ascorbyl-2 phosphate against skin damage induced by UVB irradiation. Photochem Photobiol 64:224-228, 1996
PubMed
6) Kanatate T, et al:Differential susceptibility of epidermal keratinocytes and neuroblastoma cells to cytotoxicity of ultraviolet-B light irradiation prevented by the oxygen radical-scavenger ascorbate-2-phosphate but not by ascorbate. Cell Mol Biol Res 41:561-567, 1995
 
7) Hata R, et al:L-ascorbic acid 2-phosphate stimu-lates collagen accumulation, cell proliferation, and formation of a three-dimensional tissuelike substance by skin fibroblasts. J Cell Physiol 138:8--16, 1989
 
8) Ikeno H, et al:Clinical Study if Safety and Efficacy of 5%Ascorbyl Phosphate Lotion to Treat Acne Scars after Glycolic Acid Peels. Cosmetic Dermatology. Vol. 16 No. 10:2003
 
9) Yamamoto I, et al:Collagen synthesis in human skin fibroblasts is stimulated by a stable from of ascorbate, 2-0-alpha-D-glucopyranosyl-bascorbic acid. J Nutr 122:871-877, 1992
 
10) Yasuoka S, et al:Topical application of a novel, water-soluble gamma-tocopherol derivative prevents UV-induced skin damage in mice. Photochem Photobiol 81:908-913, 2005
PubMed
11) Pinnell SR, et al:Ferulic acid stabilizes a solution of vitamins C and E and doubles its photoprotection of skin. J Invest Dermatol 125:826-832, 2005
 

書評

最近チェックした商品履歴

Loading...